WO2022234639A1 - 変異型ｒａｓ（ｇ１２ｄ）に対する選択的結合性を示す結合分子 - Google Patents

変異型ｒａｓ（ｇ１２ｄ）に対する選択的結合性を示す結合分子 Download PDF

Info

Publication number
WO2022234639A1
WO2022234639A1 PCT/JP2021/017466 JP2021017466W WO2022234639A1 WO 2022234639 A1 WO2022234639 A1 WO 2022234639A1 JP 2021017466 W JP2021017466 W JP 2021017466W WO 2022234639 A1 WO2022234639 A1 WO 2022234639A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
carbonyl
undecone
butan
methylpropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/017466
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
哲 橋本
竜児 林
沙紀 南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to PCT/JP2021/017466 priority Critical patent/WO2022234639A1/ja
Priority to CN202280027920.5A priority patent/CN117177987A/zh
Priority to PCT/JP2022/019541 priority patent/WO2022234851A1/ja
Priority to US18/289,071 priority patent/US20240239842A1/en
Priority to EP22798955.5A priority patent/EP4339204A4/en
Priority to JP2023518699A priority patent/JPWO2022234851A1/ja
Publication of WO2022234639A1 publication Critical patent/WO2022234639A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present disclosure relates to binding molecules that exhibit selective binding to mutant RAS (G12D).
  • RAS is a protein belonging to the small GTPase family, known as KRAS, NRAS, and HRAS.
  • the inactivated state or activated state of RAS is defined by the state of binding with GDP or GTP, and is activated by the exchange reaction of GDP to GTP by GEF (guanine nucleotide exchange factor), and GAP (GTPase-activating proteins ) is inactivated by the hydrolysis reaction of GTP (Non-Patent Document 1).
  • Activated RAS induces cell proliferation, survival, and differentiation by activating various downstream signals such as the MAPK pathway, PI3K/Akt pathway, and RAL pathway, and constitutive activation of RAS is associated with cancer development. and play an important role in progression.
  • Non-patent Reference 2 It is known that in cancer, the RAS-RAF-MEK-ERK pathway is activated by activation of RAS upstream signals, constitutive activation of RAS, and/or activating mutations of RAS (non-patent Reference 2). These RAS activating mutations are found in many cancer types. G12, G13, and Q61 are known to be RAS mutation hotspots, and mutations are frequently observed in G12 in KRAS and Q61 in NRAS. It is also known that these mutations are associated with patient prognosis (Non-Patent Document 3).
  • the representative KRAS G12 mutations are G12D, G12V, and G12C. Among them, the number of cancer patients with the KRAS G12D mutation is the largest, and a therapeutic drug for G12D mutation cancer is desired.
  • Patent Document 2 low-molecular-weight compounds
  • Patent Document 1 several cyclic peptide compounds
  • Patent Document 1 Non-Patent Document 4 and Non-Patent Document 5 disclose peptide compounds that exhibit a certain degree of selective binding to KRAS G12D. In order to use these peptide compounds as effective pharmaceutical active ingredients, it is necessary to discover even better selective binding properties. However, the systematic mechanism of what kind of binding morphology should be achieved to improve selective binding to mutant RAS (G12D) has not been elucidated so far.
  • the present inventors conducted intensive studies and found, surprisingly, that the binding selectivity of the compound to mutant RAS (G12D) is dramatically improved by satisfying the following conditions. I found out. 1. The compound interacts with Asp12 in mutant RAS (G12D). 2. The compound interacts with the Switch2 region in the mutant RAS (G12D), and the Switch2 region in the mutant RAS (G12D) and the Asp12 in the mutant RAS (G12D) are intramolecularly interacting.
  • [6] The binding molecule of any one of [1] to [5], wherein the mutant RAS (G12D) is mutant KRAS (G12D).
  • [7] The binding molecule of any one of [1] to [6], wherein the mutant RAS (G12D) is in GDP form.
  • [8] The binding molecule according to any one of [1] to [7], wherein the Switch2 region comprises Ala59 to Glu76.
  • [12] The binding molecule of any one of [1] to [11], which interacts with any one or more amino acid residues selected from the group consisting of Gln61 to Met72 in the Switch2 region.
  • [14] interacting with any one or more amino acid residues selected from the group consisting of Gln61, Glu62, Arg68, Asp69, and Met72 in the Switch2 region, [1] to [13] according to any one of binding molecule.
  • [16] The binding molecule according to any one of [1] to [15], comprising an amino acid residue that interacts with Gln61, wherein each of all atoms of the amino acid residue that interacts with Gln61; The binding molecule, wherein the sum of interaction energies with each of all atoms of Gln61 is -10 kcal/mol or less.
  • [17] The binding molecule of any one of [2] to [16], wherein the ⁇ 3 helix region in the mutant RAS (G12D) comprises Thr87 to Lys104.
  • [27] Includes structure (2) that is *-(linear or branched C 1 -C 8 alkylene)-Y, where Y is optionally substituted C 1 -C 10 alkyl, substituted optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted C 1 -C 6 alkoxy C 1 -C 6 alkyl, optionally substituted C 6
  • the binding molecule according to any one of [1] to [26], which is -C 10 aryl, or optionally substituted C 3 -C 8 cycloalkyl, and * means the point of attachment.
  • R 9 is C 1 -C 6 alkyl, optionally substituted C 1 -C 6 alkoxyC 1 -C 6 alkyl, or optionally substituted C 6 -C 10 aryl, or R 9 together with P 9 , the carbon atom to which R 9 is attached, and the nitrogen atom to which P 9 is attached form a 4- to 7-membered saturated heterocyclic ring
  • P 9 is hydrogen or C 1 -C 3 alkyl, except when R 9 and P 9 form a 4- to 7-membered saturated heterocyclic ring
  • Q 9 is hydrogen or C 1 -C 6 alkyl
  • * means a point of attachment.
  • the binding molecule of any one of [1] to [37] having the following structure: In the formula: A 7 and A 8 are independently any amino acid residue or any peptide residue, and A 7 and A 8 may be linked; R 7 is -(linear or branched C 1 -C 8 alkylene)-X
  • a 8 and A 9 are independently any amino acid residue or any peptide residue, and A 8 and A 9 may be linked;
  • R 8 is —(linear or branched C 1 -C 8 alkylene)—Y, Y is optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted C 1 -C6 alkoxyC1 -C6 alkyl, optionally substituted C6 - C10 aryl , or optionally substituted C3 - C8 cycloalkyl ;
  • P 8 is hydrogen or C 1 -C 3 alkyl;
  • R 9 is C 1 -C 6 alkyl, optionally substituted C 1 -C 6 alkoxyC 1 -C 6 alkyl, or optionally substituted C 6 -C 10 aryl, or R 9
  • A7 and A9 are independently any amino acid residue or any peptide residue, and A7 and A9 may be linked;
  • R 7 is -(linear or branched C 1 -C 8 alkylene)-X or -(linear or branched C 1 -C 8 alkylene)-(C 6 -C 10 arylene)-X;
  • X is hydroxy, Cl, Br, I, —NR A R B (where R A and R B are both hydrogen, each independently C 1 -C 3 alkyl, or R A and R B together with the nitrogen atoms to which they are attached form a 4-8 membered heterocyclic ring containing 1-3 heteroatoms selected from the group consisting of N, O, and S) , C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, —C ⁇ CH, or optionally substituted C 3 -C 8 cycloalkyl
  • [45] The binding molecule of any one of [1] to [44], wherein the interaction with Asp12 is not mediated by other molecules.
  • the mutant RAS (G12D) according to any one of [1] to [45], wherein an amino acid residue present in the Switch2 region and Asp12 intramolecularly interact without the intervention of another molecule; binding molecule.
  • novel binding molecules with high binding selectivity to mutant RAS (G12D) were provided. Binding molecules in the present disclosure have a 5-fold or greater selectivity for binding mutant RAS (G12D) over wild-type RAS. In addition, the present disclosure clarified the binding form of mutant RAS (G12D) and a binding molecule, which is required to achieve high binding selectivity to mutant RAS (G12D). Molecules that bind to mutant RAS (G12D) in the binding form revealed by the present disclosure are expected as therapeutic candidate molecules in the treatment and/or prevention of diseases involving the expression of mutant RAS (G12D).
  • FIG. 1 is the overall structure of the X-ray crystal structure of the complex of compound 1 and mutant RAS (G12D) shown in Example 1.
  • FIG. Mutant RAS (G12D) is shown as ribbon representation, compound 1 and guanosine diphosphate (GDP) as stick representation.
  • 2 is the overall structure of the X-ray crystal structure of the complex of Compound 2 and mutant RAS (G12D) shown in Example 2.
  • FIG. Mutant RAS (G12D) is shown as ribbon representation, compound 2 and guanosine diphosphate (GDP) as stick representation.
  • 3 is the overall structure of the X-ray crystal structure of the complex of compound 3 and mutant RAS (G12D) shown in Example 3.
  • FIG. Mutant RAS (G12D) is shown as ribbon representation, compound 3 and guanosine diphosphate (GDP) as stick representation.
  • alkyl refers to a monovalent group derived from an aliphatic hydrocarbon by removing any one hydrogen atom, and heteroatoms (other than carbon and hydrogen atoms) in the skeleton. or a subset of hydrocarbyl or hydrocarbon radical structures containing hydrogen and carbon atoms without unsaturated carbon-carbon bonds. Alkyl includes not only straight chain but also branched chain. Specific examples of alkyl include alkyl having 1 to 20 carbon atoms (C 1 to C 20 , hereinafter “C p to C q ” means having p to q carbon atoms), C 1 -C 10 alkyl is preferred, and C 1 -C 6 alkyl is more preferred.
  • alkyl examples include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, isobutyl (2-methylpropyl), n-pentyl, s-pentyl (1- methylbutyl), t-pentyl (1,1-dimethylpropyl), neopentyl (2,2-dimethylpropyl), isopentyl (3-methylbutyl), 3-pentyl (1-ethylpropyl), 1,2-dimethylpropyl, 2 -methylbutyl, n-hexyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1,1,2,2-tetramethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl , 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-
  • alkenyl refers to monovalent radicals having at least one double bond (two adjacent SP 2 carbon atoms). Depending on the configuration of the double bond and substituents (if any), the geometry of the double bond can be
  • E Electrode
  • Z Zero
  • Alkenyl includes not only straight-chain but also branched ones. Alkenyl preferably includes C 2 -C 10 alkenyl, more preferably C 2 -C 6 alkenyl, and specific examples include vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl. (including cis and trans), 3-butenyl, pentenyl, 3-methyl-2-butenyl, hexenyl and the like.
  • alkynyl refers to monovalent radicals having at least one triple bond (two adjacent SP carbon atoms). Alkynyl includes not only straight chain but also branched ones. Alkynyl preferably includes C 2 -C 10 alkynyl, more preferably C 2 -C 6 alkynyl, and specific examples include ethynyl, 1-propynyl, propargyl, 3-butynyl, pentynyl, hexynyl, 3-phenyl.
  • cycloalkyl means a saturated or partially saturated cyclic monovalent aliphatic hydrocarbon group, including monocyclic, bicyclocyclic and spirocyclic rings. Cycloalkyl preferably includes C 3 -C 8 cycloalkyl, and specific examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]heptyl, spiro[ 3.3]heptyl and the like.
  • aryl means a monovalent aromatic hydrocarbon ring, preferably C 6 -C 10 aryl. Specific examples of aryl include phenyl, naphthyl (eg, 1-naphthyl, 2-naphthyl), and the like.
  • haloalkyl means a group in which one or more hydrogen atoms of “alkyl” defined above is replaced with halogen, preferably C 1 -C 6 haloalkyl, C 1 -C 6 fluoroalkyl is more preferred.
  • haloalkyl include difluoromethyl, trifluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3,3-difluoropropyl, 4,4-difluorobutyl, 5,5 - difluoropentyl and the like.
  • alkoxyalkyl means a group in which one or more hydrogens of “alkyl” defined above is replaced with “alkoxy” defined above, and C 1 -C 6 alkoxy C 1 -C 6 alkyl is preferred and C 1 -C 6 alkoxy C 1 -C 2 alkyl is more preferred.
  • Specific examples of alkoxyalkyl include methoxymethyl, ethoxymethyl, 1-propoxymethyl, 2-propoxymethyl, n-butoxymethyl, i-butoxymethyl, s-butoxymethyl, t-butoxymethyl, pentyloxymethyl, 3-methylbutoxymethyl, 1-methoxyethyl, 2-methoxyethyl, 2-ethoxyethyl and the like.
  • alkylene means a divalent group derived from the above “alkyl” by further removing one hydrogen atom, preferably C 1 -C 8 alkylene.
  • alkylene include -CH 2 -, -(CH 2 ) 2 -, -(CH 2 ) 3 -, -CH(CH 3 )CH 2 -, -C(CH 3 ) 2 -, -(CH 2 ) 4- , -CH( CH3 ) CH2CH2- , -C ( CH3 ) 2CH2- , -CH2CH ( CH3 )CH2-, -CH2C ( CH3 ) 2- , -CH 2 CH 2 CH(CH 3 )-, -(CH 2 ) 5 -, -(CH 2 ) 6 -, -(CH 2 ) 7 -, -(CH 2 ) 8 - and the like.
  • arylene means a divalent group derived by further removing one hydrogen atom from the above "aryl”.
  • Arylene may be monocyclic or condensed. Although the number of atoms constituting the ring is not particularly limited, it is preferably 6-10 (C 6-10 arylene).
  • Specific examples of arylene include 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 1,2-naphthylene, 1,3-naphthylene and 1,4-naphthylene.
  • heterocyclic ring means a non-aromatic heterocyclic ring containing preferably 1 to 5, more preferably 1 to 3 heteroatoms among the atoms constituting the ring. Heterocycles may have double and/or triple bonds in the ring, carbon atoms in the ring may be oxidized to form carbonyls, and may be monocyclic, fused, or spirocyclic.
  • the number of atoms constituting the ring is preferably 3 to 12 (3- to 12-membered heterocyclic ring), more preferably 4 to 8 (4- to 8-membered heterocyclic ring).
  • heterocyclic rings include azetidine ring, oxetane ring, tetrahydrofuran ring, tetrahydropyran ring, morpholine ring, thiomorpholine ring, pyrrolidine ring, 4-oxopyrrolidine ring, piperidine ring, 4-oxopiperidine ring, and piperazine.
  • saturated heterocycle herein is meant a non-aromatic heterocycle containing from 1 to 5 heteroatoms in addition to carbon atoms and no double and/or triple bonds in the ring. do.
  • the saturated heterocyclic ring may be monocyclic, or may form a condensed ring with another ring such as an aromatic ring such as a benzene ring.
  • the saturated heterocyclic ring preferably includes a 4- to 7-membered saturated heterocyclic ring, and specific examples include, for example, azetidine ring, oxetane ring, tetrahydrofuran ring, tetrahydropyran ring, morpholine ring, thiomorpholine ring, pyrrolidine ring, 4-oxo pyrrolidine ring, piperidine ring, 4-oxopiperidine ring, piperazine ring, pyrazolidine ring, imidazolidine ring, oxazolidine ring, isoxazolidine ring, thiazolidine ring, isothiazolidine ring, thiadiazolidine ring, oxazolidone ring, dioxolane ring, dioxane ring, thietane ring, octahydroindole ring, indoline ring and the like.
  • peptide refers to a peptide in which 1, 2, 3, 4, 5 or more natural amino acids and/or non-natural amino acids are linked by amide bonds and/or ester bonds.
  • amino acid includes natural amino acids and non-natural amino acids.
  • natural amino acids include Gly, Ala, Ser, Thr, Val, Leu, Ile, Phe, Tyr, Trp, His, Glu, Asp, Gln, Asn, Cys, Met, Lys, Arg, Pro point to Non-natural amino acids are not particularly limited, but are exemplified by ⁇ -amino acids, ⁇ -amino acids, D-amino acids, N-substituted amino acids, ⁇ , ⁇ -disubstituted amino acids, amino acids whose side chains are different from natural ones, and hydroxycarboxylic acids. Any configuration is acceptable for the amino acids herein.
  • the side chains of amino acids are not particularly limited, but may be selected freely from, for example, alkyl groups, alkenyl groups, alkynyl groups, aryl groups, heteroaryl groups, aralkyl groups, and cycloalkyl groups in addition to hydrogen atoms.
  • One or two non-adjacent methylene groups in the group may be substituted with an oxygen atom, a carbonyl group (--CO--), or a sulfonyl group ( --SO.sub.2-- ).
  • each may be given a substituent, and these substituents are not limited, for example, any substituent containing a halogen atom, an O atom, an S atom, an N atom, a B atom, a Si atom, or a P atom
  • substituents are not limited, for example, any substituent containing a halogen atom, an O atom, an S atom, an N atom, a B atom, a Si atom, or a P atom
  • substituents are not limited, for example, any substituent containing a halogen atom, an O atom, an S atom, an N atom, a B atom, a Si atom, or a P atom
  • Examples include optionally substituted alkyl groups, alkenyl groups, alkynyl groups, aryl groups, heteroaryl groups, aralkyl groups, cycloalkyl groups and the like.
  • the amino acid herein may be a compound having a carboxy
  • the backbone amino group of an amino acid can be unsubstituted ( NH2 group) or optionally substituted (i.e. -NHR group: R is optionally substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, cycloalkyl, wherein 1 or 2 non-adjacent methylene groups in these groups are substituted with an oxygen atom, a carbonyl group (--CO--), or a sulfonyl group (--SO 2 --);
  • the carbon chain bonded to the N atom and the carbon atom at the ⁇ -position may form a ring like proline).
  • the substituents for R are selected in the same manner as the substituents in the amino acid side chains described above.
  • the aforementioned R when the main chain amino group is substituted is included in the "side chain of amino acid" in the present specification.
  • Amino acids in which such backbone amino groups are substituted are referred to herein as "N-substituted amino acids.”
  • the "N-substituted amino acid” in the present specification is preferably exemplified by N-alkylamino acid, N-C1-C6 alkylamino acid, N - C1 - C4 alkylamino acid and N - methylamino acid. is not limited to
  • amino acids that make up the peptide compounds herein include all corresponding isotopes.
  • An “amino acid” isotope is one in which at least one atom has been replaced with an atom having the same atomic number (proton number) but a different mass number (proton plus neutron number).
  • isotopes included in the "amino acids” that make up the peptide compounds in the present disclosure include hydrogen atom, carbon atom, nitrogen atom, oxygen atom, phosphorus atom, sulfur atom, fluorine atom, chlorine atom, etc., respectively, 2H , 3H , 13C , 14C , 15N , 17O , 18O , 31P , 32P , 35S , 18F , 36Cl and the like are included.
  • Examples of the substituent containing a halogen atom in the present specification include an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aralkyl group and the like having a halogen as a substituent, and more specifically is exemplified by fluoroalkyl, difluoroalkyl, trifluoroalkyl and the like.
  • oxy examples include alkoxy, cycloalkoxy, alkenyloxy, alkynyloxy, aryloxy, heteroaryloxy, aralkyloxy and the like.
  • Alkoxy is preferably C 1 -C 4 alkoxy, C 1 -C 2 alkoxy, and more preferably methoxy or ethoxy.
  • Examples of oxycarbonyl include alkyloxycarbonyl, cycloalkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkyloxycarbonyl and the like.
  • Examples of carbonyloxy include alkylcarbonyloxy, cycloalkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, aralkylcarbonyloxy and the like. .
  • thiocarbonyl examples include alkylthiocarbonyl, cycloalkylthiocarbonyl, alkenylthiocarbonyl, alkynylthiocarbonyl, arylthiocarbonyl, heteroarylthiocarbonyl, aralkylthiocarbonyl and the like.
  • Examples of carbonylthio include alkylcarbonylthio, cycloalkylcarbonylthio, alkenylcarbonylthio, alkynylcarbonylthio, arylcarbonylthio, heteroarylcarbonylthio, aralkylcarbonylthio and the like. .
  • aminocarbonyl examples include alkylaminocarbonyl (e.g. C 1 -C 6 or C 1 -C 4 alkylaminocarbonyl, especially ethylaminocarbonyl, methylaminocarbonyl, etc.) ), cycloalkylaminocarbonyl, alkenylaminocarbonyl, alkynylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl and the like.
  • alkylaminocarbonyl e.g. C 1 -C 6 or C 1 -C 4 alkylaminocarbonyl, especially ethylaminocarbonyl, methylaminocarbonyl, etc.
  • cycloalkylaminocarbonyl alkenylaminocarbonyl, alkynylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl
  • Examples of carbonylamino include alkylcarbonylamino, cycloalkylcarbonylamino, alkenylcarbonylamino, alkynylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, aralkylcarbonylamino and the like. .
  • Examples of oxycarbonylamino include alkoxycarbonylamino, cycloalkoxycarbonylamino, alkenyloxycarbonylamino, alkynyloxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, aralkyloxy carbonylamino and the like.
  • Examples of sulfonylamino include alkylsulfonylamino, cycloalkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, aralkylsulfonylamino, and the like.
  • groups in which the H atom attached to the N atom in —NH—SO 2 —R is further substituted with alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl.
  • aminosulfonyl examples include alkylaminosulfonyl, cycloalkylaminosulfonyl, alkenylaminosulfonyl, alkynylaminosulfonyl, arylaminosulfonyl, heteroarylaminosulfonyl, aralkylaminosulfonyl, and the like.
  • groups in which the H atom attached to the N atom in —SO 2 —NHR is further substituted with alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl.
  • sulfamoylamino examples include alkylsulfamoylamino, cycloalkylsulfamoylamino, alkenylsulfamoylamino, alkynylsulfamoylamino, arylsulfamoylamino, hetero arylsulfamoylamino, aralkylsulfamoylamino and the like.
  • the two H atoms attached to the N atom in —NH—SO 2 —NHR are substituents independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl. It may be substituted and these two substituents may form a ring.
  • thio are selected from alkylthio, cycloalkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio, aralkylthio and the like.
  • sulfonyl examples include alkylsulfonyl, cycloalkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, and the like.
  • secondary amino examples include alkylamino, cycloalkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, aralkylamino and the like.
  • tertiary amino examples include, for example, alkyl(aralkyl)amino, independently among alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and the like. and an amino group having any two substituents selected by , and these two arbitrary substituents may form a ring.
  • Specific examples include dialkylamino, especially C 1 -C 6 dialkylamino, C 1 -C 4 dialkylamino, dimethylamino and diethylamino.
  • C p -C q dialkylamino group refers to a group in which an amino group is substituted with two C p -C q alkyl groups, and both C p -C q alkyl groups are the same. may also be different.
  • substituted amidinos are those in which the three substituents R, R', and R'' on the N atom are alkyl, cycloalkyl, alkenyl, alkynyl, aryl, hetero Groups independently selected from aryl and aralkyl, such as alkyl(aralkyl)(aryl)amidino and the like.
  • aminocarbonylamino (-NR-CO-NR'R) is a Examples thereof include independently selected groups, groups formed by forming a ring, and the like.
  • amino acid residue that constitutes the peptide compound
  • amino acid the amino acid residue
  • peptide the amino acid residue
  • a binding molecule herein can be a salt thereof, preferably a chemically or pharmaceutically acceptable salt thereof. Binding molecules or salts thereof in the present disclosure can also be solvates thereof, preferably chemically or pharmaceutically acceptable solvates thereof. Salts of binding molecules in the present disclosure include, for example, hydrochloride; hydrobromide; hydroiodide; phosphate; phosphonate; sulfonates of; carboxylates such as acetates, citrates, malate, tartrates, succinates, salicylates; or alkali metal salts such as sodium salts, potassium salts; magnesium salts, calcium salts, etc.
  • alkaline earth metal salts such as ammonium salts, alkylammonium salts, dialkylammonium salts, trialkylammonium salts and tetraalkylammonium salts.
  • ammonium salts such as ammonium salts, alkylammonium salts, dialkylammonium salts, trialkylammonium salts and tetraalkylammonium salts.
  • These salts are produced, for example, by contacting the binding molecule with an acid or base that can be used in the production of pharmaceuticals.
  • a solvate of a binding molecule refers to a phenomenon in which a solute molecule strongly attracts a solvent molecule in solution to form a group of molecules, and is called a hydrate if the solvent is water.
  • hydrates are preferred, and such hydrates are specifically 1-10 hydrates, preferably 1-5 hydrates, more preferably 1-10 hydrates, and more preferably 1-10 hydrates.
  • a trihydrate can be mentioned.
  • Solvates of binding molecules in the present disclosure include solvates with single solvents such as water, alcohols (e.g., methanol, ethanol, 1-propanol, 2-propanol, etc.), dimethylformamide, as well as multiple Solvates with solvents are also included.
  • One or more as used herein means one or two or more numbers. When “one or more” is used in the context of substituents on a group, the term means from one to the maximum number of substituents allowed by the group. “One or more” specifically includes, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and/or greater.
  • to indicating a range includes values at both ends thereof, for example, "A to B” means a range of A or more and B or less.
  • the term "about” when used in combination with a numerical value means a value range of +10% and -10% of that numerical value.
  • the meaning of the term “and/or” includes all combinations in which “and” and “or” are appropriately combined.
  • “A, B, and/or C” includes the following seven variations; (i) A, (ii) B, (iii) C, (iv) A and B, (v) A and C, (vi) B and C, (vii) A, B, and C.
  • the present disclosure relates to binding molecules that have the following features (1) and (2) and that have a binding selectivity to mutant RAS (G12D) that is 5 times or more that of wild-type RAS.
  • a binding molecule interacts with Asp12 in said mutant RAS (G12D); and (2) a binding molecule interacts with the Switch2 region in said mutant RAS (G12D) and said mutant RAS.
  • G12D an amino acid residue present in the Switch2 region and Asp12 intramolecularly interact.
  • a binding molecule having selective binding activity for mutant RAS (G12D) in the present disclosure may further have the following characteristics. (3) when the binding molecule interacts with the ⁇ 3 helix region in the mutant RAS (G12D), and/or (4) when the amino acid residue present in the Switch2 region and Asp12 are intramolecularly interacting , in the mutant RAS (G12D), the distance between the ⁇ carbon atom in Asp69 present in the Switch2 region and the ⁇ carbon atom in Gln99 present in the ⁇ 3 helix region is 15.0 angstroms ( ⁇ ) It is below.
  • binding molecule means a molecule that can bind to a certain molecule.
  • molecule A is said to be a binding molecule of molecule B if molecule A can bind to molecule B.
  • a binding molecule in the present disclosure is a molecule that selectively binds to mutant RAS (G12D).
  • mutant RAS (G12D) refers to RAS containing a mutation from glycine (Gly) to aspartic acid (Asp) at the 12th amino acid residue in wild-type RAS.
  • the mutant RAS (G12D) in the present disclosure may have amino acid residue mutations at other sites as long as it includes a glycine (Gly) to aspartic acid (Asp) mutation at the 12th amino acid residue. .
  • Mutations at other sites include glycine (Gly) to aspartic acid (Asp) or valine (Val) at amino acid residue 13, alanine (Ala) to serine (Ser) at amino acid residue 59, or Glycine (Gly), Glutamine (Gln) to Histidine (His), Lysine (Lys) or Leucine (Leu) at amino acid residue 61, Tyrosine (Tyr) at amino acid residue 96 Mutations to aspartic acid (Asp), leucine (Leu) or serine (Ser) can be exemplified.
  • mutant RAS is not particularly limited, and various animals such as humans, mice, rats, rabbits, dogs, cats, cows, horses, pigs, goats, rhesus monkeys, cynomolgus monkeys, chimpanzees, and chickens.
  • Mutant RAS (G12D) may be included, but mutant RAS (G12D) in the present disclosure is preferably human-derived mutant RAS (G12D).
  • As isoforms of RAS three types of NRAS, HRAS, and KRAS are known.
  • amino acid sequence of human-derived wild-type NRAS is shown in SEQ ID NO: 2
  • amino acid sequence of human-derived wild-type HRAS is shown in SEQ ID NO: 3
  • amino acid sequence of human-derived wild-type KRAS is shown in SEQ ID NO: 4.
  • mutant RAS (G12D) in the present disclosure is not limited as long as it includes a mutation from glycine (Gly) to aspartic acid (Asp) at the 12th amino acid residue of these wild-type NRAS, HRAS, and KRAS.
  • mutant KRAS (G12D) is preferred, and human-derived mutant KRAS (G12D) is more preferred.
  • the amino acid sequence of human-derived KRAS (G12D) is shown in SEQ ID NO:5.
  • RAS is known to have an inactivated state bound to GDP and an activated state bound to GTP.
  • the mutant RAS (G12D) in the present disclosure may be in either the GTP form or the GDP form, preferably the GDP form.
  • binding molecule in the present disclosure has high binding selectivity for binding mutant RAS (G12D) to wild-type RAS. Also, in one non-limiting aspect, the binding molecule of the present disclosure has high binding activity to mutant RAS (G12D).
  • the binding selectivity for mutant RAS (G12D) over wild-type RAS is determined from the ratio of the binding activity of the binding molecule of the present disclosure to wild-type RAS and the binding activity of the binding molecule of the present disclosure to mutant RAS (G12D). be able to.
  • the binding selectivity for mutant RAS ( G12D ) as compared to wild-type RAS is expressed as [the dissociation constant (K value) of the binding molecule of the present disclosure for wild-type RAS].
  • K D value dissociation constant
  • binding selectivity to mutant RAS (G12D) relative to wild-type RAS is low.
  • binding molecules in the present disclosure have a binding selectivity for mutant RAS (G12D) over wild-type RAS of 5-fold or more, 6-fold or more, 7-fold or more, 8-fold or more, 9-fold or more. It is preferably twice or more, 10 times or more, 11 times or more, 12 times or more, 13 times or more, 14 times or more, or 15 times or more.
  • binding activity refers to the intrinsic binding affinity that reflects a 1:1 interaction between a member of a binding pair (e.g., a binding molecule and mutant RAS (G12D) or wild-type RAS in this disclosure).
  • binding affinity and dissociation constant K D
  • a surface plasmon resonance method BIACORE, etc.
  • the binding and dissociation rate constants (kon) and dissociation rate constants (koff) were calculated using a one-to-one Langmuir binding model (Biacore Insight Evaluation Software, GE) by simultaneously fitting the binding and dissociation sensorgrams. Healthcare)), etc.
  • the dissociation constant (K D ) is calculated as the koff/kon ratio.
  • the temperature during measurement can be 30° C.
  • the running buffer is HBS containing 1 mM DTT, 10 mM MgCl2, 0.01% Tween20, 10 ⁇ M GDP and 4% DMSO (10 mM HEPES-NaOH, 150 mM NaCl, pH 7 .4) can be used, and measurements can be performed in a state in which biotinylated Avi-tag-fused wild-type RAS or mutant RAS is immobilized on the surface of Sensor Chip CAP (Cytiva) coated with Biotin CAPture Reagent. .
  • Binding molecules in the present disclosure have high avidity for mutant RAS (G12D).
  • the dissociation constant (K D ) of the binding molecule for mutant RAS (G12D) in the present disclosure is 10.0 nM or less, 9.0 nM or less, 8.0 nM or less, 7.0 nM or less, 6.0 nM or less. , 5.0 nM or less, 4.0 nM or less, or 3.0 nM or less.
  • binding molecules in the present disclosure interact with Asp12 of mutant RAS (G12D).
  • a binding molecule in the present disclosure can be a molecule capable of interacting with Asp12 of mutant RAS (G12D).
  • the interaction between the binding molecule and mutant RAS (G12D) with Asp12 is preferably a direct interaction not mediated by other molecules. Therefore, the binding molecule in the present disclosure can be a molecule capable of directly interacting with the Asp12 amino acid residue of mutant RAS (G12D) without the presence of other molecules or the like. Water molecules are exemplified as other molecules, but are not limited thereto.
  • a binding molecule in the present disclosure can be a molecule capable of causing a direct interaction between mutant RAS (G12D) and Asp12.
  • atoms involved in interaction with Asp12 of mutant RAS (G12D) in the binding molecule constitute Asp12. 4.50 ⁇ or less, 4.40 ⁇ or less, 4.30 ⁇ or less, 4.20 ⁇ or less, 4.10 ⁇ or less, 4.00 ⁇ or less, 3.95 ⁇ or less 90 ⁇ or less, 3.85 ⁇ or less, 3.80 ⁇ or less, 3.75 ⁇ or less, 3.70 ⁇ or less, 3.65 ⁇ or less, 3.60 ⁇ or less, 3.55 ⁇ or less, 3.50 ⁇ or less, 3.45 ⁇ or less, 3.
  • Atoms of the binding molecule that interact with Asp12 of mutant RAS include, for example, iodine located at the 3-position of the phenyl group of phenylalanine or homophenylalanine. Atoms constituting Asp12 that interact with the binding molecule include, for example, two oxygen atoms of the carboxy group contained in Asp12.
  • the interatomic distance is the iodine located at the 3-position of the phenyl group of phenylalanine or homophenylalanine contained in the binding molecule and the carboxyl group contained in Asp12 of the mutant RAS (G12D). and the iodine located at the 3-position of the phenyl group of phenylalanine or homophenylalanine contained in the binding molecule, and the carboxyl group contained in Asp12 of the mutant RAS (G12D).
  • the shorter one is preferred.
  • a binding molecule in the present disclosure may have a structure capable of causing a direct interaction between mutant RAS (G12D) and Asp12.
  • the structure capable of causing direct interaction between mutant RAS (G12D) and Asp12 is not particularly limited, but from the viewpoint of making it easier to cause direct interaction with Asp12, * Structure (1) which is -(linear or branched C 1 -C 8 alkylene)-X or *-(linear or branched C 1 -C 8 alkylene)-(C 6 -C 10 arylene)-X can be exemplified.
  • X is hydroxy, Cl, Br, I, —NR A R B (wherein R A and R B are both hydrogen, each independently C 1 -C 3 alkyl, or R A and R B together with the nitrogen atom to which they are attached form a 4-8 membered heterocyclic ring containing 1-3 heteroatoms selected from the group consisting of N, O, and S ), C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, —C ⁇ CH, or optionally substituted C 3 -C 8 cycloalkyl, * denotes the point of attachment.
  • X does not contain C 1 -C 3 alkyl.
  • the above structure (1) may also be involved in the effect of facilitating the intramolecular interaction between the amino acid residues present in the Switch2 region and Asp12.
  • -(linear or branched C 1 -C 8 alkylene)-(C 6 -C 10 arylene)- is benzyl or phenethyl and X is at the 3-position of the phenyl group.
  • Structure (1) is particularly preferably: can be exemplified.
  • two oxygen atoms of a carboxy group can be exemplified as atoms contained in Asp12 of mutant RAS (G12D) involved in direct interaction.
  • the binding molecule in the present disclosure is a peptide compound
  • the peptide compound comprises one or more amino acid residues that interact with Asp12 of mutant RAS (G12D).
  • the amino acid residue is preferably an ⁇ -amino acid residue. More specifically, ⁇ -amino acid residues having structure (1) on the side chain can be exemplified.
  • binding molecules in the present disclosure interact with the Switch2 region in mutant RAS (G12D).
  • the Switch2 region in this disclosure includes Ala59-Glu76 in the mutant RAS (G12D) represented by SEQ ID NO:6.
  • the Switch2 region in the present disclosure consists of Ala59-Glu76 in mutant RAS (G12D). Therefore, the binding molecule of the present disclosure is a binding molecule capable of interacting with any one or more amino acid residues selected from the group consisting of Ala59 to Glu76 in the Switch2 region of mutant RAS (G12D). can.
  • the binding molecule in the present disclosure is selected from the group consisting of Gln61 to Met72 of the Switch2 region (amino acid sequence set forth in SEQ ID NO: 7) from the viewpoint of facilitating interaction with the Switch2 region.
  • a molecule that interacts with one or more (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11) amino acid residues can be done.
  • the binding molecule in the present disclosure is preferably one or more (1, 2, 3 or 4) selected from the group consisting of Gln61, Glu62, Arg68, Asp69 and Met72 in the Switch2 region. ) amino acid residues.
  • the binding molecule in the present disclosure can more preferably be a molecule that interacts with Gln61 in the Switch2 region.
  • the binding molecule in the present disclosure is a peptide compound
  • the peptide compound preferably contains one or more amino acid residues that interact with those amino acid residues in the Switch2 region of mutant RAS (G12D).
  • the amino acid residue is preferably an ⁇ -amino acid residue.
  • binding molecules include one or more (e.g., a molecule having 2, 3, or 4) amino acid residues, one or more (e.g., two , or 3) amino acid residues, and 1 or Molecules having multiple (eg, 2, 3, 4, or 5) amino acid residues can be exemplified, but not limited to.
  • the interaction energy between the binding molecule of the present disclosure and GLN61 in the Switch2 region is a large negative value, indicating that the binding molecule and the Switch2 region are strongly interacting.
  • the binding molecule in the present disclosure is a peptide compound having amino acid residues that interact with Gln61 of the Switch2 region
  • each of all atoms of the peptide compound and all of the Gln61 amino acid residues is, for example, -7.0 kcal/ mol or less, preferably -10 kcal/mol or less, more preferably -11.0 kcal/mol or less, still more preferably -13.0 kcal/mol or less, even more preferably -15.0 kcal/mol or less, still more preferably -16.
  • the interaction between the binding molecule and the Switch2 region of mutant RAS (G12D) is preferably an interaction that does not involve other molecules.
  • binding molecules in the present disclosure interact with the ⁇ 3 helical region of mutant RAS (G12D).
  • the ⁇ 3 helical region in mutant RAS (G12D) in the present disclosure comprises Thr87-Lys104 in mutant RAS (G12D), represented by SEQ ID NO:8.
  • the ⁇ 3 helical region in the present disclosure consists of Thr87-Lys104 in mutant RAS (G12D).
  • the binding molecule in the present disclosure can be a binding molecule capable of interacting with amino acid residues consisting of Thr87-Lys104 of the Switch2 region in mutant RAS (G12D).
  • the binding molecule of the present disclosure is selected from the group consisting of Thr87 to Lys104 of the ⁇ 3 helical region in mutant RAS (G12D), from the viewpoint of facilitating interaction between the binding molecule and the ⁇ 3 helical region. Any one or more selected (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18) amino acid residues.
  • the binding molecule in the present disclosure is preferably any one or more (1, 2, 3, 4, 5, 6) selected from the group consisting of His95 to Val103 (SEQ ID NO: 9) in the Switch2 region , 7, 8, or 9) amino acid residues.
  • the binding molecule in the present disclosure is more preferably any one or more selected from the group consisting of His95, Tyr96, Gln99, Arg102, and Val103 in the Switch2 region (1, 2, 3, 4, or 5) amino acid residues, and particularly preferably a molecule that interacts with Gln99 in the Switch2 region.
  • the binding molecule in the present disclosure is a peptide compound
  • the peptide compound contains one or more amino acid residues that interact with these amino acid residues in the ⁇ 3 helix region of mutant RAS (G12D).
  • the amino acid residue is preferably an ⁇ -amino acid residue.
  • binding molecules interact with one or more (e.g., 2, 3, 4, or 5) of His95, Tyr96, Gln99, Arg102, and Val103 in the ⁇ 3 helix region.
  • a molecule having one or more (eg, 2, 3, 4, or 5) amino acid residues, one or more (eg, 2, 3, or 4) of His95, Tyr96, Gln99, and Val103 and one or more (eg, two) of His95, Tyr96, Gln99, Arg102, and Val103. , 3, 4, or 5) can be exemplified by molecules having one or more (e.g., 2, 3, 4, or 5) amino acid residues that interact with Not limited.
  • the interaction between the binding molecule and the ⁇ 3 helix region of mutant RAS (G12D) is preferably an interaction that does not involve other molecules. .
  • the Switch2 region in the mutant RAS (G12D) and the ⁇ 3 helical region are in close proximity.
  • the distance between the ⁇ carbon atom in Asp69 present in the Switch2 region of mutant RAS (G12D) and the ⁇ carbon atom in Gln99 present in the ⁇ 3 helix region is approximately 15.0 angstroms ( ⁇ ) or less, preferably about 14.0 ⁇ or less, more preferably about 13.0 ⁇ or less, even more preferably about 12.0 ⁇ or less, and most preferably about 11.0 ⁇ or less.
  • the binding molecule of the present disclosure forms a complex with the mutant RAS (G12D), the ⁇ carbon atom in Asp69 present in the Switch2 region and the ⁇ 3 helix region in the mutant RAS (G12D)
  • This close distance between the ⁇ -carbon atoms in Gln99 is thought to facilitate intramolecular interactions between the amino acid residues present in the Switch2 region and Asp12, the present disclosure.
  • the binding molecule in the present disclosure is such that the distance between the ⁇ carbon atom in Asp69 present in the Switch2 region and the ⁇ carbon atom in Gln99 present in the ⁇ 3 helical region in mutant RAS (G12D) is 15.0 angstroms. ( ⁇ ) or less, 14.0 ⁇ or less, 13.0 ⁇ or less, 12.0 ⁇ or less, or 11.0 ⁇ or less.
  • the amino acid residues present in the Switch2 region that interacts with Asp12 are any one or more selected from the group consisting of Ala59, Gly60, Gln61, and Glu62 (1 , 2, 3 or 4).
  • the main chain atoms of at least one, at least two, at least three, or four of these amino acid residues are either one of the two oxygen atoms of the carboxy group of Asp12, or Preferably, they are within about 4.5 angstroms ( ⁇ ) of both.
  • the total action energy is, for example, -10.5 kcal/mol or less, -13.0 kcal/mol or less, -15.0 kcal/mol or less, -15.5 kcal/mol or less, -16.0 kcal/mol or less, -16. It can be, but is not limited to, 5 kcal/mol or less, -17.0 kcal/mol or less, -17.5 kcal/mol or less, or -18.0 kcal/mol or less.
  • a binding molecule in the present disclosure can be a molecule capable of causing preorientation in mutant RAS (G12D).
  • a binding molecule in the present disclosure may also have a structure capable of causing preorientation in mutant RAS (G12D).
  • structures capable of causing prior orientation in mutant RAS (G12D) are not particularly limited, but structures that are *-(linear or branched C 1 -C 8 alkylene)-Y (2) can be exemplified.
  • Y is optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted C 1 -C 6 alkoxy C 1 -C 6 alkyl, optionally substituted C 6 -C 10 aryl, or optionally substituted C 3 -C 8 cycloalkyl, * denotes point of attachment .
  • More preferred embodiments of structure (2) are *-(CH 2 )-Y, *-(CH 2 ) 2 -Y, etc., where Y is C 3 -C 8 alkyl, C 3 -C 8 cyclo C 6 -C 10 aryl optionally substituted by alkyl, C 3 -C 8 alkenyl, or C 1 -C 6 alkoxy.
  • Structure (2) is particularly preferably: can be exemplified.
  • the binding molecule in the present disclosure can include the following structure (3) as a structure capable of causing prior orientation in mutant RAS (G12D).
  • R 9 is C 1 -C 6 alkyl, optionally substituted C 1 -C 6 alkoxyC 1 -C 6 alkyl, or optionally substituted C 6 -C 10 aryl, or R 9 together with P 9 , the carbon atom to which R 9 is attached, and the nitrogen atom to which P 9 is attached form a 4- to 7-membered saturated heterocyclic ring
  • P 9 is hydrogen or C 1 -C 3 alkyl, except when R 9 and P 9 form a 4- to 7-membered saturated heterocyclic ring
  • Q 9 is hydrogen or C 1 -C 6 alkyl; * means a point of attachment.
  • R 9 is preferably C 1 -C 4 alkyl, phenyl C 1 -C 2 alkyl, C 1 -C 3 alkoxyC 1 -C 2 alkyl. Also, when R 9 is C 1 -C 4 alkyl, Q 9 is preferably C 1 -C 4 alkyl, more preferably methyl. When R 9 is phenyl C 1 -C 2 alkyl, or C 1 -C 3 alkoxyC 1 -C 2 alkyl, Q 9 is preferably hydrogen. P9 is preferably methyl. .
  • the 4- to 7-membered saturated heterocyclic ring is preferably an azetidine ring, a pyrrolidine ring or a piperidine ring, more preferably a pyrrolidine ring.
  • Q 9 is preferably C 1 -C 6 alkyl, more preferably methyl.
  • Structure (3) is particularly preferably: can be exemplified.
  • the binding molecule in the present disclosure is the atom farthest from the binding point of structure (1) among the atoms contained in X in structure (1), and the structure ( Among the atoms contained in Y in 2), the atom farthest from the bonding point of structure (2) is within 20 (for example, 19, 18, 17, 16, 15, 14, or or less) atoms.
  • the binding molecule in the present disclosure is included in X in structure (1), except when R 9 and P 9 form a 4- to 7-membered saturated heterocyclic ring.
  • the carbons bonded to Q 9 and R 9 in structure (3) the farthest atom from the atom is bonded through no more than 25 atoms (e.g., 24, 23, 22, 21, 20, 19, 18, 17, 16, or less) preferably.
  • the "interaction" in the present disclosure means that the atoms of the side chain or main chain in the amino acid residue forming the mutant RAS (G12D) and the atoms constituting the binding molecule in the present disclosure are the following (1) to Interatomic distances that can provide at least one, preferably two, more preferably three, and particularly preferably four of each feature of (4), or at least each of the following features (1) to (4) Included are states in which the mutant RAS (G12D) and the binding molecule are interacting with interatomic energies that can provide one, preferably two, more preferably three, and particularly preferably four. (1) The binding molecule interacts with Asp12 in mutant RAS (G12D).
  • the binding molecule interacts with the Switch2 region in the mutant RAS (G12D), and in the mutant RAS (G12D), amino acid residues present in the Switch2 region and Asp12 intramolecularly interact.
  • the binding molecule interacts with the ⁇ 3 helical region in mutant RAS (G12D); (4) When the amino acid residue present in the Switch2 region and Asp12 are intramolecularly interacting, in the mutant RAS (G12D), the ⁇ carbon atom in Asp69 present in the Switch2 region and the ⁇ 3 helix region
  • the distance between the existing ⁇ -carbon atoms in Gln99 is 15.0 angstroms ( ⁇ ) or less.
  • the structural information of the complex of the binding molecule and mutant RAS (G12D) in the present disclosure is transferred to a software program used for molecular modeling or molecular simulation such as Discovery studio 2020 Client, MOE (Molecular Operating Environment), Maestro, etc. If you load it and use the function built into the software program (for example, in the case of Discovery studio 2020 Client, the Display receptor-ligand interactions function), which amino acid residues make up the mutant RAS (G12D) It is possible to determine whether residues interact with the binding molecule.
  • interaction refers to non-electrostatic interactions (including ionic bonds, hydrogen bonds and dipole interactions), van der Waals interactions (including hydrophobic interactions), and the like.
  • a covalent interaction is meant.
  • the interaction in the present disclosure may be mediated by other molecules such as water molecules or may not be mediated by other molecules such as water molecules. is preferably
  • a non-hydrogen atom contained in a specific amino acid residue of mutant RAS interacts with a non-hydrogen atom contained in a molecule that interacts with the It can be determined by the interatomic distance between hydrogen atoms (in the case of a bond via another molecule such as a water molecule, the interatomic distance between both non-hydrogen atoms ignoring the other molecule). It can be determined that both non-hydrogen atoms interact when the interatomic distance is 4.6 angstroms ( ⁇ ) or less.
  • the interatomic distance between two interacting non-hydrogen atoms is, for example, 4.5 ⁇ or less, 4.2 ⁇ or less, 4.0 ⁇ or less, 3.7 ⁇ or less, 3.5 ⁇ or less, 3 .2 ⁇ or less, or 3.0 ⁇ or less.
  • the thickness may be 2.0 ⁇ or more, 2.1 ⁇ or more, or 2.5 ⁇ or more.
  • the interatomic distance between the two interacting non-hydrogen atoms is, for example, 5.5 ⁇ or less, 5.0 ⁇ or less, 4.5 ⁇ or less, 4.2 ⁇ or less, 4.0 ⁇ . , 3.7 ⁇ or less, 3.5 ⁇ or less, or 3.2 ⁇ or less.
  • the interatomic distance can be measured, for example, through analysis of the three-dimensional structure of the complex of mutant RAS (G12D) and the binding molecule in the present disclosure. Specifically, crystals of complexes of mutant RAS (G12D) and binding molecules of the present disclosure are prepared. X-ray diffraction of the crystal is performed to obtain X-ray diffraction intensity data such as space group and unit cell. Acquired X-ray diffraction intensity data were compared with Coot (Emsley, P. et al., 2010), Phenix (Adams, P.D. et al., 2010), Phaser (J. Appl. Cryst.
  • the three-dimensional structure of the complex of mutant RAS (G12D) and the binding molecule in the present disclosure can be determined, it is possible to measure the interatomic distance by methods well known to those skilled in the art.
  • the structural information of the complex of the binding molecule and mutant RAS (G12D) in the present disclosure is transferred to a software program used for molecular modeling or molecular simulation such as Discovery studio 2020 Client, MOE (Molecular Operating Environment), Maestro, etc. It is possible to measure the interatomic distance by loading and using the function built into the software program (for example, the Distance Monitor function in the case of Discovery studio 2020 Client).
  • a crystal of the complex of mutant RAS (G12D) and the binding molecule of the present disclosure can also be obtained by methods well known to those skilled in the art.
  • a solution containing the binding molecule of the present disclosure and a solution containing mutant RAS (G12D) are mixed to obtain a complex of mutant RAS (G12D) and the binding molecule of the present disclosure.
  • Mutant RAS (G12D) and Crystals of complexes of binding molecules in the present disclosure can be prepared.
  • a sitting drop method, a hanging drop method, and a sandwich drop method are known as vapor diffusion methods.
  • mutant RAS (G12D) can also be obtained by a method known to those skilled in the art.
  • mutant RAS (G12D) can be prepared using recombinant polypeptide expression methods using cells, but is not limited to this.
  • a nucleic acid encoding a mutant RAS (G12D) of the present disclosure is inserted into a suitable expression vector, the vector is introduced into a suitable cell, and the transformed cells are cultured to express the modified Proteins are isolated, purified and cultured.
  • Such proteins can also be expressed as fusion proteins with other proteins for purposes such as facilitating purification.
  • a method of preparing a fusion protein with maltose-binding protein using Escherichia coli as a host (vector pMAL series sold by New England BioLabs, USA), a method of preparing a fusion protein with glutathione-S-transferase (GST) (Amersham Pharmacia Biotech vector pGEX series sold by the company), preparation by adding histidine tag (pET series by Novagen), preparation by adding HAT tag, and the like can be used.
  • Host cells are not particularly limited as long as they are suitable for expression of recombinant proteins, and in addition to the above E. coli, yeast, various animal and plant cells, insect cells and the like can be used.
  • a protein expressed in a host cell can be purified and recovered from the host cell or its cell culture or culture supernatant by methods known to those skilled in the art.
  • affinity purification or gel filtration chromatography size exclusion chromatography, SEC
  • AKTAxpressTM instrument GE Healthcare
  • NGCTM chromatography system Bio-Rad
  • BioLogic DuoFlowTM chromatography system Bio-Rad
  • the interatomic energy can also be measured by methods well known to those skilled in the art.
  • a molecular simulation program known to those skilled in the art such as Discovery studio 2020 Client, MOE (Molecular Operating Environment), Maestro, etc., reads the 3D structure of the substance to be measured and uses it for calculation according to the instructions of the program. It can be easily calculated by selecting a force field (eg Amber, CHARM, etc.) and an atom for energy calculation.
  • a force field eg Amber, CHARM, etc.
  • interatomic energy can be calculated using the Calculate Interaction Energy function.
  • the binding molecule of the present disclosure interacts with Asp12 in mutant RAS (G12D) (direct interaction).
  • the binding molecule in the present disclosure interacts with the Switch2 region in mutant RAS (G12D). Then, the atoms constituting the Switch2 region (specifically, the ⁇ carbon atom in Asp69) and the atoms constituting the ⁇ 3 helix region (specifically, the ⁇ carbon atom in the amino acid residue Gln99) in the mutant RAS (G12D) are close to each other. This is thought to be related to the intramolecular interaction between amino acid residues (for example, Gln61) constituting the Switch2 region in mutant RAS (G12D) and Asp12 (pre-orientation).
  • the binding molecule of the present disclosure and mutant RAS (G12D) form a complex in such a manner that the binding molecule of the present disclosure mutant RAS (G12D) ) and contribute to the binding selectivity.
  • the molecular weight of the binding molecule in the present disclosure is preferably 5000 or less, more preferably 3000 or less, from the viewpoint of further enhancing the binding selectivity of the binding molecule to mutant RAS (G12D) relative to wild-type RAS. , more preferably 2500 or less, more preferably 2300 or less, still more preferably 2000 or less, preferably 500 or more, more preferably 800 or more, still more preferably 1000 or more.
  • the molecular weight of the peptide compound can be preferably 500 or more and 5000 or less, more preferably 800 or more and 3000 or less, even more preferably 1000 or more and 2000 or less.
  • the CLogP of the binding molecule in the present disclosure is preferably 25 or less, more preferably 22 or less, even more preferably 20 or less, even more preferably 18 or less, even more preferably 16 or less. , more preferably 15 or less, preferably 5 or more, more preferably 10 or more, still more preferably 12 or more.
  • the CLogP of the peptide compound can be preferably 5 or more and 25 or less, more preferably 10 or more and 20 or less, even more preferably 12 or more and 18 or less.
  • ClogP herein is a computer calculated partition coefficient, which can be calculated using Daylight Chemical Information Systems, Inc.'s Daylight Version 4.9.
  • ClogP/total aa of the peptide compound is preferably 1.0 or more, more preferably 1.1 or more, and even more preferably 1.2 or more, 1.8 or less, 1.7 or less, 1.6 or less, 1.5 or less are preferably exemplified, 1.0 or more and 1.8 or less, 1.0 or more and 1.7 or less, 1.1 or more and 1.6 or less , and 1.1 to 1.5 are exemplified.
  • total aa (also referred to as "total AA”) means the number of amino acids that constitute a peptide compound.
  • binding molecules in the present disclosure include, but are not limited to, small compounds, peptide compounds, polypeptides, proteins, antibodies, carbohydrates, nucleic acids, and derivatives thereof. In one non-limiting aspect, binding molecules in the present disclosure also include salts or solvates thereof.
  • a binding molecule in the present disclosure may be a peptide compound, and a peptide compound may be a cyclic peptide compound.
  • peptide compounds in the present disclosure may include one or more natural and non-natural amino acid residues. The ratio of these amino acids is not particularly limited.
  • a non-natural amino acid residue in the present disclosure may be an N-substituted amino acid residue.
  • N-substituted amino acids may preferably be N-alkyl amino acids, more preferably N-methyl amino acids.
  • the N-substituted amino acid may preferably be a ring formed by the carbon chain attached to the N-atom and the carbon atom at the ⁇ -position, such as proline.
  • the total number of amino acid residues contained in the peptide compound of the present disclosure is preferably 4 or more, from the viewpoint of enhancing the binding selectivity of the binding molecule to mutant RAS (G12D) over wild-type RAS, More preferably 5 or more, still more preferably 6 or more, still more preferably 8 or more, still more preferably 9 or more, still more preferably 10 or more, preferably 30 or less, more preferably 20 or less, still more preferably 15 or less, and further It may be preferably 14 or less, more preferably 13 or less, still more preferably 12 or less, and most preferably 11.
  • the cyclic peptide compound of the present disclosure preferably has a total number of amino acids contained in the cyclic portion of 5 or more, more preferably 7 or more, still more preferably 8 or more, still more preferably 9 or more, still more preferably 10 or more. , preferably 15 or less, more preferably 13 or less, still more preferably 12 or less, and most preferably 11.
  • the number of amino acid residues in the linear portion is preferably 0 or more and 17 or less, more preferably 0 or more and 8 or less. It is preferably 0 or more and 5 or less, and particularly preferably 0 or more and 3 or less.
  • the “linear portion” in the present specification may include natural amino acid residues and non-natural amino acid residues (including chemically modified and skeleton-converted amino acids).
  • the number of unnatural amino acids contained in the peptide compound of the present disclosure is preferably 3 or more, more preferably 4 or more, 5 or more, or 6 or more, even more preferably 7 or more, and further preferably 8 or more. 9 or less is particularly preferable, and 20 or less, 15 or less, 14 or less, 13 or less, 12 or less, or 10 or less is preferably exemplified.
  • Examples of the number of unnatural amino acids contained in the peptide compound of the present disclosure include 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, and 80% or more of the number of amino acids contained in the peptide compound. be done.
  • the number of N-substituted amino acid residues contained in the peptide compound of the present disclosure is preferably 3 or more, more preferably 4 or more, 5 or more, or 6 or more, and even more preferably 7 or more. Below, 15 or less, 14 or less, 13 or less, 12 or less, 10 or less, 9 or less, and 8 or less are preferably exemplified.
  • the number of N-substituted amino acids contained in the peptide compound of the present disclosure is exemplified by 30% or more, 40% or more, 50% or more, 60% or more of the number of amino acids constituting the peptide compound.
  • the number of non-natural amino acid residues other than N-substituted amino acid residues contained in the peptide compound of the present disclosure is preferably 3 or more, more preferably 4 or more, 5 or more, or 6 or more, and 7 8 or less is more preferable, and 20 or less, 15 or less, 14 or less, 13 or less, 12 or less, 10 or less, and 9 or less are preferably exemplified.
  • Examples of the number of N-substituted amino acids contained in the peptide compound of the present disclosure include 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, and 80% or more of the number of amino acids constituting the peptide compound. be done.
  • the peptide compound when the binding molecule in the present disclosure is a peptide compound, the peptide compound has the following structure (4 ).
  • a 7 and A 8 are independently any amino acid residue or any peptide residue, and A 7 and A 8 may be linked;
  • R 7 is -(linear or branched C 1 -C 8 alkylene)-X or -(linear or branched C 1 -C 8 alkylene)-(C 6 -C 10 arylene)-X;
  • X is hydroxy, Cl, Br, I, —NR A R B (where R A and R B are both hydrogen, each independently C 1 -C 3 alkyl, or R A and R B together with the nitrogen atoms to which they are attached form a 4-8 membered heterocyclic ring containing 1-3 heteroatoms selected from the group consisting of N, O, and S) , C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, —C ⁇ CH, or optionally
  • R 7 and X are those in which R 7 is benzyl or phenethyl and X is ethyl, cyclopropyl, Cl, Br, I, or -C ⁇ CH at the 3-position of the phenyl group, more preferably is benzyl or phenethyl, and X is I at the 3 -position of the phenyl group, or -C ⁇ CH.
  • P7 is preferably hydrogen or methyl.
  • R 8 is preferably -(CH 2 )-Y or -(CH 2 ) 2 -Y, where Y is C 3 -C 8 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 alkenyl, or It is preferably C 6 -C 10 aryl optionally substituted by C 1 -C 6 alkoxy.
  • P8 is preferably hydrogen or methyl.
  • amino acid residue can be any natural or non-natural amino acid residue.
  • said peptide residues may be composed of any type and number of natural and/or non-natural amino acid residues.
  • the number of amino acid residues constituting the peptide residue is preferably 2-13, more preferably 2-9.
  • A7 and A8 can be linked.
  • the peptide residue formed by joining A7 and A8 can include any number and type of natural and/or non - natural amino acid residues.
  • the peptide residues preferably consist of 5 to 15 amino acid residues, more preferably 8 or 9 amino acid residues.
  • Structure (4) is particularly preferably: can be exemplified.
  • the binding molecule in the present disclosure is a peptide compound
  • the peptide compound has the following structure in which structure (2) and structure (3) in the present disclosure are linked via an amide bond: (5).
  • a 8 and A 9 are independently any amino acid residue or any peptide residue, and A 8 and A 9 may be linked;
  • R 8 is —(linear or branched C 1 -C 8 alkylene)—Y, Y is optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted C 1 -C6 alkoxyC1 -C6 alkyl, optionally substituted C6 - C10 aryl , or optionally substituted C3 - C8 cycloalkyl ;
  • P 8 is hydrogen or C 1 -C 3 alkyl;
  • R 9 is C 1 -C 6 alkyl, optionally substituted C 1 -
  • R 8 is preferably -(CH 2 )-Y or -(CH 2 ) 2 -Y, where Y is C 3 -C 8 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 alkenyl, or It is preferably C 6 -C 10 aryl optionally substituted by C 1 -C 6 alkoxy.
  • P8 is preferably hydrogen or methyl.
  • R 9 is preferably C 1 -C 4 alkyl, phenyl C 1 -C 2 alkyl, C 1 -C 3 alkoxyC 1 -C 2 alkyl. Also, when R 9 is C 1 -C 4 alkyl, Q 9 is preferably C 1 -C 4 alkyl, more preferably methyl. When R 9 is phenyl C 1 -C 2 alkyl, or C 1 -C 3 alkoxyC 1 -C 2 alkyl, Q 9 is preferably hydrogen. P9 is preferably methyl.
  • the 4- to 7-membered saturated heterocyclic ring is preferably an azetidine ring, a pyrrolidine ring or a piperidine ring, more preferably a pyrrolidine ring.
  • Q 9 is preferably C 1 -C 6 alkyl, more preferably methyl.
  • amino acid residue can be any natural or non-natural amino acid residue.
  • a 8 and/or A 9 is a peptide residue
  • said peptide residue may be composed of any kind and number of natural and/or non-natural amino acid residues.
  • the number of amino acid residues constituting the peptide residue is preferably 2-13, more preferably 2-9.
  • a 8 and A 9 can be linked.
  • the peptide residue formed by joining A 8 and A 9 can include any number and type of natural and/or non-natural amino acid residues.
  • the peptide residues preferably consist of 5 to 15 amino acid residues, more preferably 8 or 9 amino acid residues.
  • structure (5) Especially preferred as structure (5) are: can be exemplified.
  • the binding molecule in the present disclosure is a peptide compound
  • the peptide compound has the following structure in which structures (1) to (3) in the present disclosure are linked via an amide bond: (6).
  • A7 and A9 are independently any amino acid residue or any peptide residue, and A7 and A9 may be linked;
  • R 7 is -(linear or branched C 1 -C 8 alkylene)-X or -(linear or branched C 1 -C 8 alkylene)-(C 6 -C 10 arylene)-X;
  • X is hydroxy, Cl, Br, I, —NR A R B (where R A and R B are both hydrogen, each independently C 1 -C 3 alkyl, or R A and R B together with the nitrogen atoms to which they are attached form a 4-8 membered heterocyclic ring containing 1-3 heteroatoms selected from the group consisting of N, O, and S) , C 1 -C 3 alkyl, C 1
  • R 7 and X are those in which R 7 is benzyl or phenethyl and X is ethyl, cyclopropyl, Cl, Br, I, or -C ⁇ CH at the 3-position of the phenyl group, more preferably is benzyl or phenethyl, and X is I at the 3 -position of the phenyl group, or -C ⁇ CH.
  • P7 is preferably hydrogen or methyl.
  • R 8 is preferably -(CH 2 )-Y or -(CH 2 ) 2 -Y, where Y is C 3 -C 8 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 alkenyl, or It is preferably C 6 -C 10 aryl optionally substituted by C 1 -C 6 alkoxy.
  • P8 is preferably hydrogen or methyl.
  • R 9 is preferably C 1 -C 4 alkyl, phenyl C 1 -C 2 alkyl, C 1 -C 3 alkoxyC 1 -C 2 alkyl. Also, when R 9 is C 1 -C 4 alkyl, Q 9 is preferably C 1 -C 4 alkyl, more preferably methyl. When R 9 is phenyl C 1 -C 2 alkyl, or C 1 -C 3 alkoxyC 1 -C 2 alkyl, Q 9 is preferably hydrogen. P9 is preferably methyl.
  • the 4- to 7-membered saturated heterocyclic ring is preferably an azetidine ring, a pyrrolidine ring or a piperidine ring, more preferably a pyrrolidine ring.
  • Q 9 is preferably C 1 -C 6 alkyl, more preferably methyl.
  • amino acid residue can be any natural or non-natural amino acid residue.
  • said peptide residues may be composed of any type and number of natural and/or non-natural amino acid residues.
  • the number of amino acid residues constituting the peptide residue is preferably 2-13, more preferably 2-9.
  • A7 and A9 can be linked.
  • the peptide residue formed by joining A7 and A9 can include any number and type of natural and/or non-natural amino acid residues.
  • the peptide residues preferably consist of 5 to 15 amino acid residues, more preferably 7 or 8 amino acid residues.
  • structure (6) Particularly preferred as structure (6) are: can be exemplified.
  • the binding molecule in the present disclosure is a peptide compound
  • the peptide compound has a 4- to 7-membered saturated heterocyclic ring for R 9 and P 9 from the viewpoint of facilitating direct interaction and prior orientation.
  • the farthest atom from the ⁇ carbon atom to which R 7 is bound is preferably bonded through no more than 25 atoms (eg, 24, 23, 22, 21, 20, 19, 18, 17, 16, or less).
  • the binding molecule in the present disclosure is preferably a binding molecule other than the following compounds.
  • a binding molecule in the present disclosure can be obtained by selecting a molecule having characteristics (1) to (4) described herein from among arbitrary molecules.
  • the binding molecules of the present disclosure can be produced, for example, using methods for chemically synthesizing polypeptides well known to those skilled in the art, or methods for expressing recombinant polypeptides using cells.
  • Examples of methods for chemically synthesizing binding molecules in the present disclosure include liquid-phase synthesis methods, solid-phase synthesis methods using Fmoc, Boc, and the like, and combinations thereof.
  • Fmoc synthesis amino acids are used as basic units, where the main chain amino group is protected by the Fmoc group, the side chain functional groups are protected by basic non-cleavable protecting groups such as piperidine, and the main chain carboxylic acid is not protected. do.
  • the basic unit is not particularly limited as long as it is a combination having an Fmoc-protected amino group and a carboxylic acid group.
  • a dipeptide may be used as a basic unit.
  • the basic unit placed at the N-terminus may be other than the Fmoc amino acid.
  • it may be a Boc amino acid or a carboxylic acid analogue without an amino group.
  • the backbone carboxylic acid groups are supported on the solid phase by chemical reaction with the functional groups of the solid support.
  • the Fmoc group is deprotected with a base such as piperidine or DBU, and the newly generated amino group and the subsequently added protected amino acid having a carboxylic acid as a basic unit are condensed to form a peptide bond.
  • a base such as piperidine or DBU
  • De-Fmoc group removal followed by repeated peptide bond forming reactions can generate the desired peptide sequence.
  • cleavage from the solid phase and, if necessary, deprotection of the protective groups for the introduced side chain functional groups are performed.
  • Cleavage from the solid phase can be performed with a weak acid such as 1% TFA, or it is possible to use Pd or the like as a protecting group to utilize the orthogonality of chemical reactions between the two. Between or at the end of these steps, steps such as cyclization can also be performed.
  • a side chain carboxylic acid can be condensed with an N-terminal main chain amino group, or a side chain amino group can be condensed with a C-terminal main chain carboxylic acid.
  • the reaction must be orthogonal between the carboxylic acid on the C-terminal side and the side chain carboxylic acid to be cyclized, or between the main chain amino group or hydroxy group on the N-terminal side and the side chain amino group to be cyclized.
  • the choice of protecting groups is made in consideration of the orthogonality of the protecting groups, as described above. It is also possible to cyclize between side chain thiol groups of cysteine residues by placing a chloroacetyl group at the N-terminus.
  • the reaction product thus obtained can be purified using a reverse phase column, a molecular sieve column, or the like.
  • binding molecules in the present disclosure can also be produced using recombinant methods and constructs.
  • a nucleic acid encoding a binding molecule of the disclosure is inserted into a suitable expression vector, the vector is introduced into a suitable cell, the transformed cells are cultured, and the expressed modified protein is isolated. , purify and culture.
  • Such proteins can also be expressed as fusion proteins with other proteins for purposes such as facilitating purification.
  • a method of preparing a fusion protein with maltose-binding protein using Escherichia coli as a host (vector pMAL series sold by New England BioLabs, USA), a method of preparing a fusion protein with glutathione-S-transferase (GST) (Amersham Pharmacia Biotech vector pGEX series sold by the company), a method of preparation by adding a histidine tag (pET series of Novagen), and the like can be used.
  • Host cells are not particularly limited as long as they are suitable for expression of recombinant proteins, and in addition to the above E. coli, yeast, various animal and plant cells, insect cells and the like can be used.
  • Various methods known to those skilled in the art can be used to introduce vectors into host cells.
  • an introduction method using calcium ions (Mandel, M., Higa, A. (1970) Journal of Molecular Biology, 53, 158-162, Hanahan, D. (1983) Journal of Molecular Biology, 166, 557-580) can be used.
  • a protein expressed in a host cell can be purified and recovered from the host cell or its cell culture or culture supernatant by methods known to those skilled in the art. When the protein is expressed as a fusion protein with the above maltose binding protein or the like, affinity purification can be easily performed.
  • production of the binding molecule of the present disclosure may include identifying the binding molecule of the present disclosure. That is, a binding molecule according to the present disclosure is a molecule having the characteristics of (1) to (4) above according to the description herein after contacting a test molecule with a mutant RAS (G12D), wherein the wild-type RAS can also be obtained by selecting binding molecules that have a 5-fold or higher binding selectivity to mutant RAS (G12D) against .
  • Test molecules in the present disclosure are not particularly limited.
  • Cell culture supernatants, fermented microbial products, marine organism extracts, plant extracts, prokaryotic cell extracts, eukaryotic single cell extracts or animal cell extracts and the like can be mentioned. These may be purified products or crudely purified products such as extracts of plants, animals or microorganisms.
  • the method for producing the test molecule is not particularly limited, and it may be isolated from natural products, chemically or biochemically synthesized, or prepared by genetic engineering. may be
  • the disclosure also provides pharmaceutical compositions containing the binding molecules of the disclosure.
  • the pharmaceutical composition of the present disclosure can be formulated by known methods by introducing a pharmaceutically acceptable carrier in addition to the binding molecule of the present disclosure, a salt of the binding molecule, or a solvate thereof. is. Excipients, binders, lubricants, coloring agents, flavoring agents and, if necessary, stabilizers, emulsifiers, absorption enhancers, surfactants, pH adjusters, preservatives, antiseptics, and An oxidizing agent or the like can be used, and ingredients generally used as raw materials for pharmaceutical formulations are blended and formulated by a conventional method.
  • an oral formulation after adding a binding molecule of the present disclosure or a salt thereof and excipients, and optionally a binder, disintegrant, lubricant, coloring agent, flavoring agent, etc., Powders, fine granules, granules, tablets, coated tablets, capsules and the like are prepared by conventional methods.
  • these components include animal and vegetable oils such as soybean oil, beef tallow, and synthetic glycerides; hydrocarbons such as liquid paraffin, squalane, and solid paraffin; ester oils such as octyldodecyl myristate and isopropyl myristate; cetostearyl alcohol, behenyl alcohol, and the like.
  • animal and vegetable oils such as soybean oil, beef tallow, and synthetic glycerides
  • hydrocarbons such as liquid paraffin, squalane, and solid paraffin
  • ester oils such as octyldodecyl myristate and isopropyl myristate
  • cetostearyl alcohol behenyl alcohol, and the like.
  • silicone resin silicone oil; polyoxyethylene fatty acid ester, sorbitan fatty acid ester, glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, surfactant such as polyoxyethylene polyoxypropylene block copolymer water-soluble polymers such as hydroxyethylcellulose, polyacrylic acid, carboxyvinyl polymer, polyethylene glycol, polyvinylpyrrolidone, methylcellulose; lower alcohols such as ethanol and isopropanol; polyhydric alcohols such as glycerin, propylene glycol, dipropylene glycol and sorbitol; Sugars such as glucose and sucrose; inorganic powders such as anhydrous silicic acid, magnesium aluminum silicate and aluminum silicate; and purified water.
  • surfactant such as polyoxyethylene polyoxypropylene block copolymer water-soluble polymers such as hydroxyethylcellulose, polyacrylic acid, carboxyvinyl polymer
  • Excipients include, for example, lactose, cornstarch, sucrose, glucose, mannitol, sorbitol, crystalline cellulose, and silicon dioxide.
  • binders include polyvinyl alcohol, polyvinyl ether, methylcellulose, ethylcellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, polypropyleneglycol-polyoxyethylene-block polymer, and meglumine. be done.
  • disintegrants examples include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium hydrogencarbonate, calcium citrate, dextrin, pectin, carboxymethylcellulose/calcium, and the like.
  • lubricants examples include magnesium stearate, talc, polyethylene glycol, silica, hydrogenated vegetable oils, and the like.
  • coloring agents those that are permitted to be added to pharmaceuticals are used, and as flavoring agents, cocoa powder, mint brain, aromatic powder, mint oil, borneol, cinnamon powder, etc. are used.
  • these tablets and granules can be coated with sugar or other appropriate coatings as necessary.
  • the binding molecule of the present disclosure or a pharmacologically acceptable salt thereof may be added with a pH adjuster, a solubilizer, a tonicity agent, etc. as necessary. Add solubilizers, stabilizers, etc. as appropriate, and formulate in a conventional manner.
  • sterile solutions or suspensions with water or other pharmaceutically acceptable liquids.
  • pharmacologically acceptable carriers or vehicles specifically sterile water, physiological saline, vegetable oils, emulsifiers, suspending agents, surfactants, stabilizers, flavoring agents, excipients, vehicles, preservatives , binders, etc., and admixed in a unit dose form required for generally accepted pharmaceutical practice.
  • compositions for injection can be formulated according to normal pharmaceutical practice using a vehicle such as distilled water for injection.
  • Aqueous solutions for injection include, for example, physiological saline, isotonic solutions containing glucose and other adjuvants, such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride.
  • isotonic solutions containing glucose and other adjuvants such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride.
  • Alcohols, particularly ethanol, polyalcohols such as propylene glycol, polyethylene glycol, nonionic surfactants such as Polysorbate 80®, HCO-50 may be used in combination.
  • Sesame oil and soybean oil are examples of oily liquids, and benzyl benzoate and benzyl alcohol may be used together as solubilizers. It may also be blended with buffers such as phosphate buffers, sodium acetate buffers, soothing agents such as procaine hydrochloride, stabilizers such as benzyl alcohol, phenol, and antioxidants.
  • buffers such as phosphate buffers, sodium acetate buffers, soothing agents such as procaine hydrochloride, stabilizers such as benzyl alcohol, phenol, and antioxidants.
  • a prepared injection solution is usually filled into a suitable ampoule.
  • administration is preferably oral administration
  • the administration method is not limited to oral administration.
  • parenteral administration include injection dosage forms, nasal dosage forms, pulmonary dosage forms, transdermal dosage forms, and the like.
  • injection dosage forms include systemic or local administration by intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection, and the like.
  • the administration method can be appropriately selected according to the patient's age and symptoms.
  • the dose of the pharmaceutical composition containing the binding molecule of the present disclosure can be selected, for example, in the range of 0.0001 mg to 1000 mg per kg of body weight per administration. Alternatively, for example, the dose can be selected in the range of 0.001 to 100000 mg/body per patient, but is not necessarily limited to these figures.
  • the dosage and administration method vary depending on the patient's body weight, age, symptoms, etc., but can be appropriately selected by those skilled in the art.
  • the binding molecules of the present disclosure can be used to inhibit the function of mutant RAS (G12D).
  • the binding molecules of the present disclosure can be used to treat or prevent a disease associated with expression of mutant RAS (G12D) in a subject. Cancer can be exemplified as such a disease.
  • the present disclosure provides cancer therapeutic agents containing the binding molecules of the present disclosure, and pharmaceutical compositions for treating and/or preventing cancer containing the binding molecules of the present disclosure.
  • the present disclosure also relates to methods for treating and/or preventing cancer comprising administering a binding molecule of the present disclosure to a subject.
  • the disclosure also relates to the use of the binding molecules of the disclosure in the preparation of a medicament for treating and/or preventing cancer. Further, the disclosure relates to binding molecules according to the disclosure for use in treating and/or preventing cancer. Examples of cancer include, but are not limited to, pancreatic cancer, colon cancer, lung cancer, and the like.
  • the term "subject” includes mammals, preferably humans.
  • the peptide was extended by the following basic route. i.e. 1) Peptide elongation reaction by the Fmoc method from the amino acid N-terminus of a 2-chlorotrityl resin loaded with an Asp side chain carboxylic acid or a D-3-Abu carboxylic acid, 2) process of cleaving peptides from 2-chlorotrityl resin, 3) By condensation of the carboxylic acid of the Asp side chain or the carboxylic acid of D-3-Abu, which is produced off the 2-chlorotrityl resin by the cleavage process, with the amino group of the N-terminal of the peptide chain (triangular unit in the scheme below).
  • Fmoc-Amino Acids Used for Peptide Synthesis by Peptide Synthesizer
  • the Fmoc- amino acids listed in Tables 2 and 3 were used for synthesis by peptide synthesizer.
  • the Fmoc-amino acids listed in Table 2 were purchased from commercial suppliers.
  • the Fmoc-amino acids listed in Table 3 were synthesized as described in this production example.
  • Nickel bromide trihydrate (NiBr 2.3H 2 O) (4 g, 0.07 eq.) and 4,4′-di-tert-butyl-2,2′-bipyridyl (dtbbpy, CAS number 72914-19- 3) (3.9 g, 14.55 mmol, 0.07 equivalent) was added to DMA (500 mL) and stirred at 50°C for 2 hours under a nitrogen atmosphere to prepare a Ni solution.
  • NiBr 2.3H 2 O 4 g, 0.07 eq.
  • dtbbpy 4,4′-di-tert-butyl-2,2′-bipyridyl
  • Trifluoroacetic acid (TFA) (2.90 mL, 37.6 mmol) was added to a toluene solution (12 mL) of the crude product compound aa004-a (1.46 g) and paraformaldehyde (377 mg, 12.54 mmol). , and stirred overnight at room temperature. After distilling off the solvent under reduced pressure, ethyl acetate was added, the organic layer was washed with a saturated aqueous sodium hydrogencarbonate solution and then with a saturated saline solution, and the resulting organic layer was dried over anhydrous magnesium sulfate and filtered. . The solvent was distilled off from the resulting filtrate under reduced pressure to obtain a crude product, compound aa004-b (2.13 g). The resulting compound aa004-b was used for the next reaction without further purification.
  • TFA Trifluoroacetic acid
  • DCE dichloroethane
  • reaction solution was filtered through celite, and the filtrate was treated with ice-cooling under a nitrogen atmosphere, triethylsilane (2.103 mL, 13.20 mmol), water (0.079 mL, 4.40 mmol), and diethyl boron trifluoride.
  • Ether complex (BF 3 OEt 2 ) (0.837 mL, 6.60 mmol) was added and stirred for 4 hours. 50% Brine was added to the reaction solution, and the mixture was further stirred at room temperature for 30 minutes. After filtration through a phase separator, the organic layer was recovered and concentrated under reduced pressure to obtain a crude product.
  • the resin site when the resin and the compound are bound, the resin site may be indicated by ⁇ .
  • the chemical structure of the reaction site may be indicated by connecting to ⁇ .
  • the 2-chlorotrityl group on the resin is linked to the side chain carboxylic acid of MeAsp via an ester bond. It shows how they are connected.
  • Cyclic peptide compounds (compound 1, compound 3, compound 5) (Table 5) were synthesized by the method described in WO2013 /100132 or WO2018/225864. Using a peptide synthesizer (Multipep RS; manufactured by Intavis), peptide synthesis was carried out by the Fmoc method, the details of which are shown below, and the detailed procedures for the operation were followed in accordance with the manual attached to the synthesizer.
  • Peptide elongation reaction from N-terminus of amino acid by Fmoc method Peptide compounds were synthesized by solid-phase synthesis using Fmoc-protected amino acids using a peptide synthesizer (Multipep RS or Multipep RSi) manufactured by Intavis. For detailed operating procedures, the manual attached to the synthesizer was followed.
  • a peptide synthesizer Multipep RS or Multipep RSi
  • Fmoc-protected amino acids (0.3-0.6 mol/L) constituting the peptide of interest, and HOAt, oxyma or HOOBt (0.375 mol/L) as carboxyl group activators were added to NMP or NMP/DMF ( 1/1) to prepare solution 1.
  • DMSO was added to 20-30% (v/v) to prepare solution 1.
  • Solution 2 was prepared by mixing N,N'-diisopropylcarbodiimide (DIC) (10% v/v) and N,N-dimethylformamide (DMF).
  • a DMF solution (2% v/v, 0.7 mL) of diazabicycloundecene (DBU) was added to the solid-phase reaction vessel containing the resin to deprotect the N-terminal Fmoc group at room temperature.
  • the deprotection of the first residue was allowed to react for 4.5 minutes, and the deprotection of the second and subsequent residues was allowed to react for 10 minutes, after which the solution was discharged from the frit.
  • DMF (0.7 mL) was added thereto, and the solution was discharged from the frit after standing for 5 minutes. This resin washing step was repeated three more times to obtain a resin in which the N-terminal Fmoc group of the amino acid or peptide bound on the resin was removed to form an amino group.
  • solution 1 (0.3 mL) and solution 2 (0.36 mL) were mixed in the mixing vial of the synthesizer, added to the deprotected resin, and the solid-phase reaction vessel was heated to 40°C. did. In the case of difficult-to-extend sequences, it was heated to 60°C as necessary.
  • the condensation reaction between the amino group on the resin and the Fmoc-protected amino acid was allowed to react for 2.5 hours. In the case of a difficult-to-extend sequence, the reaction was allowed to proceed for 20 hours, if necessary. After reaction, the solution was drained from the frit. If the elongation efficiency was low, this Fmoc-protected amino acid condensation reaction was repeated one or two more times.
  • the resin was then washed three times with DMF (0.7 mL). This deprotection reaction of the Fmoc group followed by the condensation reaction of the Fmoc amino acid was regarded as one cycle, and this cycle was repeated to elongate the peptide on the resin surface. After completion of the peptide elongation, a solution of diazabicycloundecene (DBU) in DMF (2% v/v, 0.7 mL) was added to the resin and allowed to react for 15 minutes to deprotect the Fmoc group. was discharged from the frit. The resulting resin was washed 4 times with DMF (0.7 mL) and then 4 times with DCM (0.7 mL).
  • DBU diazabicycloundecene
  • a condensation cyclization reaction between the N-terminal amino group and the C-terminal carboxyl group was carried out.
  • the equivalent number was calculated based on the product of the amount of resin used (usually 100 mg) and the amino acid loading rate (mmol/g) of the resin used as the raw material.
  • the reaction solution was distilled under reduced pressure using a high-throughput centrifugal evaporator (HT-12 manufactured by Genevac) to remove the solvent.
  • Example 1 Compound 1 ((3S,6S,9S,12S,18S,27S,30S,34S)-9-(cyclohexylmethyl)-12-[(3-iodophenyl)methyl]-3,30-diisobutyl-6 -(Methoxymethyl)-1,7,16,19,22,25,31-heptamethyl-27-[(1S)-1-methylpropyl]-34-(piperidine-1-carbonyl)-18-(p- tolylmethyl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotetratriacontane-2,5,8,11,14,17,20,23,26, 29,32-undecone) Compound 1
  • Example 2 Compound 2 ((1S,6S,9S,15S,18S,21S,24S,27S,31S,34S)-21-benzyl-34-cyclobutyl-9-[(4,4-difluorocyclohexyl)methyl]- 15-[(3-iodophenyl)methyl]-24,31-diisobutyl-8,11,20,26,30-pentamethyl-18-(3-methylbut-2-enyl)-27-(piperidine-1-carbonyl )-3,8,11,14,17,20,23,26,30,33,36-undecazatricyclo[34.4.0.03,6]tetracontane-2,7,10,13,16,19, 22,25,29,32,35-undecaone) Compound 2
  • the resin was washed sequentially with DMF (0.7 mL x 4 times), DCM (0.7 mL x 2 times), and toluene (0.7 mL x 2 times).
  • a toluene solution (2% v/v, 0.7 mL) of diazabicycloundecene (DBU) was added thereto and allowed to react for 10 minutes to deprotect the Fmoc group.
  • DBU diazabicycloundecene
  • DBU diazabicycloundecene
  • reaction solution was distilled under reduced pressure using a high-throughput centrifugal evaporator (HT-12) manufactured by Genevac.
  • Example 3 Compound 3 ((3S,6S,9S,12S,18S,27S,30S,34S)-9-butyl-12-[(3-iodophenyl)methyl]-3-isobutyl-30-(2-methoxy Ethyl)-6-(methoxymethyl)-1,7,16,19,22,25,31-heptamethyl-27-[(1S)-1-methylpropyl]-34-(piperidine-1-carbonyl)-18 -(p-tolylmethyl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotetratriacontane-2,5,8,11,14,17,20, 23,26,29,32-undecone) compound 3
  • Compound 3 was manufactured according to the manufacturing method of compound 1.
  • the resin was washed sequentially with DMF (0.7 mL x 4 times), DCM (0.7 mL x 2 times), and toluene (0.7 mL x 2 times).
  • a toluene solution (2% v/v, 0.7 mL) of diazabicycloundecene (DBU) was added thereto and allowed to react for 10 minutes to deprotect the Fmoc group.
  • DBU diazabicycloundecene
  • DBU diazabicycloundecene
  • reaction solution was distilled under reduced pressure using a high-throughput centrifugal evaporator (HT-12) manufactured by Genevac.
  • Compound 5 was manufactured according to the manufacturing method of Compound 1.
  • Evaluation example 1 X-ray crystal structure analysis of KRASG12D and peptide compound complex 1.
  • Construction of human KRASG12D mutant protein For the human KRASG12D mutant protein [Uniprot ID: P01116, based on Isoform 2B], a HAT (histidine affinity tag) tag sequence and a thrombin recognition sequence were added to the N-terminus of the expression region 2-174.
  • An additional construct HATnorTh-hKRAS(G12D)_APOLLO-01 was designed. Its amino acid sequence is shown in SEQ ID NO:1.
  • the designed gene was incorporated into the pETBlue-1 vector and transformed into E. coli strain Tuner(DE3)pLacI [Novagen] for use with the E. coli expression system.
  • LB Lysogeny Broth
  • IPTG Isopropyl ⁇ -D-1-thiogalactopyranoside
  • EDTA Complete Protease Inhibitor
  • the supernatant of the obtained cell lysate was purified under the following conditions.
  • the supernatant of the cell lysate was purified using cOmplete His-Tag Purification Column [Roche 6781543001] and BioLogic DuoFlow [Bio-Rad]. After the column was equilibrated with Buffer A (50 mM Tris-HCl, 400 mM NaCl, 1% CHAPS, 5% Glycerol, 1 mM DTT, pH 8.0), the cell lysate supernatant was loaded onto the column. KRASG12D mutant protein was adsorbed to the column.
  • Buffer A After washing the column with Buffer A, apply a concentration gradient of Buffer A and Buffer B (50 mM Tris-HCl, 400 mM NaCl, 1% CHAPS, 5% Glycerol, 1 M Imidazole, 1 mM DTT, pH 8.0).
  • Buffer B 50 mM Tris-HCl, 400 mM NaCl, 1% CHAPS, 5% Glycerol, 1 M Imidazole, 1 mM DTT, pH 8.0.
  • the human KRASG12D mutant protein was eluted by mixing and running. The eluted fraction containing the human KRASG12D mutant protein was concentrated, added with thrombin [Sigma T6634], and dialyzed at 15°C in Dialysis buffer (50 mM Tris-HCl, 400 mM NaCl, 1 mM DTT, pH 8.0). This cleaved the HAT (histidine affinity tag) tag added for purification.
  • HAT histidine
  • the ratio of the external and internal solutions for dialysis was 100:1.
  • NaCl was added to the dialyzed sample to a final concentration of 0.8 M
  • Benzamidine Sepharose 4 Fast Flow equilibrated with Buffer C 50 mM Tris-HCl, 800 mM NaCl, 1 mM DTT, pH 8.0. [GE healthcare 17-5123-10] was added.
  • Buffer D 150 mM Tris-HCl, pH 7.6, 1.5 M Arginine-HCl
  • SEC size exclusion chromatography
  • Buffer A After washing the column with Buffer A, apply a concentration gradient of Buffer A and Buffer B (50 mM Tris-HCl, 400 mM NaCl, 1% CHAPS, 5% Glycerol, 1 M Imidazole, 1 mM DTT, pH 8.0).
  • Buffer B 50 mM Tris-HCl, 400 mM NaCl, 1% CHAPS, 5% Glycerol, 1 M Imidazole, 1 mM DTT, pH 8.0.
  • the human KRASG12D mutant protein was eluted by mixing and running. The eluted fraction containing the human KRASG12D mutant protein was concentrated, added with thrombin [Sigma T6634], and dialyzed at 15°C in Dialysis buffer (50 mM Tris-HCl, 400 mM NaCl, 1 mM DTT, pH 8.0). This cleaved the HAT (histidine affinity tag) tag added for purification.
  • HAT histidine
  • the ratio of the external and internal solutions for dialysis was 100:1.
  • NaCl was added to the dialyzed sample to a final concentration of 0.8 M
  • Benzamidine Sepharose 4 Fast Flow equilibrated with Buffer C 50 mM Tris-HCl, 800 mM NaCl, 1 mM DTT, pH 8.0). (GE healthcare 17-5123-10) was added.
  • Buffer D 150 mM Tris-HCl, pH 7.6, 1.5 M Arginine-HCl
  • SEC size exclusion chromatography
  • Buffer A After washing the column with Buffer A, apply a concentration gradient of Buffer A and Buffer B (50 mM Tris-HCl, 400 mM NaCl, 1% CHAPS, 5% Glycerol, 1 M Imidazole, 1 mM DTT, pH 8.0).
  • Buffer B 50 mM Tris-HCl, 400 mM NaCl, 1% CHAPS, 5% Glycerol, 1 M Imidazole, 1 mM DTT, pH 8.0.
  • the human KRASG12D mutant protein was eluted by mixing and running. The eluted fraction containing the human KRASG12D mutant protein was concentrated, thrombin [GE healthcare 27-0846-01] was added, and dialysis buffer (50 mM Tris-HCl, 400 mM NaCl, 1 mM DTT, pH 8.0) was added.
  • the HAT tag added for purification was cleaved by dialysis at 20°C.
  • the ratio of the external and internal solutions for dialysis was 100:1.
  • Benzamidine Sepharose 4 Fast Flow equilibrated with Buffer C 50 mM Tris-HCl, 800 mM NaCl, 1 mM DTT, pH 8.0
  • Buffer C 50 mM Tris-HCl, 800 mM NaCl, 1 mM DTT, pH 8.0
  • Benzamidine Sepharose 4 Fast Flow was removed and concentrated by centrifugation after 2 hours.
  • SEC size exclusion chromatography
  • the human KRASG12D mutant protein was eluted by mixing and running.
  • the eluted fraction containing the human KRASG12D mutant protein was concentrated, thrombin [GE healthcare 27-0846-01] was added, and dialysis buffer (50 mM Tris-HCl, 400 mM NaCl, 1 mM DTT, pH 8.0) was added.
  • dialysis buffer 50 mM Tris-HCl, 400 mM NaCl, 1 mM DTT, pH 8.0
  • the HAT tag added for purification was cleaved by dialysis at 20°C. The ratio of the external and internal solutions for dialysis was 100:1.
  • Benzamidine Sepharose 4 Fast Flow [GE healthcare 17-5123-10] equilibrated with Benzamidine Sepharose 4 Fast Flow was removed and concentrated by centrifugation after 2 hours.
  • SEC size exclusion chromatography purification was performed using a gel filtration column HiLoad 16/600 Superdex 75pg [GE healthcare 28-9893-33] and a cOmplete His-Tag Purification Column 1mL [Roche 06781543001] chromatography system. .
  • the final SEC buffer conditions used were 20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 100 mM NaCl, 1 mM DTT, 5 mM MgCl 2 , pH was 8.0.
  • the human KRASG12D mutant protein was diluted to 1 mg/mL using KRAS buffer (20 mM HEPES, 100 mM NaCl, 5 mM MgCl2, 1 mM DTT pH7.1). . 10 mM of compounds 1 to 5 dissolved in 100% DMSO (dimethyl sulfoxide), and compound 4 using KRAS buffer (20 mM HEPES, 100 mM NaCl, 5 mM MgCl 2 , 1 mM DTT pH7.1).
  • KRAS buffer (20 mM HEPES (pH7.1),, 100 mM NaCl, 5 mM MgCl2, 1 mM DTT pH7.1) was used for compounds 1, 2 and 3, and pure water was used for compound 5. Diluted to 1 mM.
  • the compound peptide compound was mixed so that the molar ratio of the compound peptide compound to the human KRASG12D mutant protein was 3 times or more as follows.
  • Compound 2 5.7 times
  • Compound 3 5.7 times
  • Compound 4 3.3 times
  • Compound 5 5.7 times
  • Compound 1 90 mM Morpheus Halogens, 0.1 M Morpheus buffer1 (pH 6.5), 30.0%w/v P550MME_P20K, 20°C
  • Compound 2 0.1 M Tris pH 8.5, 25.0%w/v Polyethylene glycol 3,350, 20°C Compound 3 : 0.2 M MgCl2, 0.1 M Tris pH 8.5, 20.0%w/v Polyethylene glycol 8,000, 20°C
  • Compound 4 0.2 M Lithium sulfate monohydrate, 0.1 M Tris pH 8.5, 30.0%w/v Polyethylene glycol 4,000, 20°C Compound 5: 30.0% w/v P550MME_P20K [550M_20K], 0.1 M Morpheus buffer 3 [MB3] (pH 8.5), 60 mM Morpheus divalents [divalent], 20°C
  • Compound 2 [Large synchrotron radiation facility] SPring-8 BL45XU (RIKEN Harima Research Institute) [Sample processing conditions] Crystals were frozen with liquid nitrogen in 0.1 M Tris pH 8.5, 25.0% w/v Polyethylene glycol 3,350, 25% Ethylene glycol used as a cryoprotectant solution. [Measurement condition] Temperature: 100K X-ray wavelength: 1.0 ⁇
  • Compound 3 [Large synchrotron radiation facility] SPring-8 BL45XU (RIKEN Harima Research Institute) [Sample processing conditions] Crystals were frozen with liquid nitrogen in 0.2 M MgCl2, 0.1 M Tris pH 8.5, 20.0%w/v Polyethylene glycol 8,000, 25% Ethylene glycol used as cryoprotectant solution. [Measurement condition] Temperature: 100K X-ray wavelength: 1.0 ⁇
  • Compound 4 [Large synchrotron radiation facility] Photon Factory BL1A (High Energy Accelerator Research Organization) [Sample processing conditions] Crystals were frozen with liquid nitrogen in 0.2 M Lithium sulfate monohydrate, 0.1 M Tris pH 8.5, 30.0% w/v Polyethylene glycol 4,000, 25% Glycerol used as a cryoprotectant solution. [Measurement condition] Temperature: 95K X-ray wavelength: 1.9 ⁇
  • Compound 5 [Large synchrotron radiation facility] Photon Factory BL17A (High Energy Accelerator Research Organization) [Sample processing conditions] Crystals were frozen in liquid nitrogen in 30.0 %w/v P550MME_P20K [550M_20K], 0.1 M Morpheus buffer 3 [MB3] (pH 8.5, 60 mM Morpheus Divalents [divalent]) used as a cryoprotectant solution. [Measurement condition] Temperature: 95K X-ray wavelength: 0.98 ⁇
  • X-ray diffraction data are autoPROC (XDS (Kabsch, W. 2010), AIMLESS (Evans, P.R. 2006), STARANISO (Tickle, I.J. et al., 2019), CCP4 (Winn, M.D. et al., 2011)) (Global Phasing Ltd.) (Vonrhein, C. et al., 2001).
  • the crystal structure was determined by molecular replacement using Phaser (McCoy, A.J. et al., 2007) using the known structure of KRAS as a search model.
  • the structures obtained were refined using Coot (Emsley, P. et al., 2010), Phenix (Adams, P.D. et al., 2010) and others.
  • FIG. 1 shows the overall structure of compound 1 and human KRASG12D mutant protein complex
  • Figure 2 shows the overall structure of compound 2 and human KRASG12D mutant protein complex
  • Figure 2 shows the overall structure of compound 3 and human KRASG12D mutant protein complex. is shown in FIG.
  • Evaluation example 2 Interaction analysis between KRASG12D and peptide compounds 1. Definition of amino acids that interact with peptide compounds Using the Display receptor-ligand interactions function of Discovery studio 2020 Client, amino acids in mutant RAS that interact with peptide compounds were identified.
  • Biacore 8K+ (GE Healthcare) was used as a compound binding evaluation device for KRAS by surface plasmon resonance (SPR), and 1 mM DTT, 10 mM MgCl2, 0.01% Tween20, 10 ⁇ M GDP and 4% DMSO were used as running buffers.
  • SPR surface plasmon resonance
  • HBS (10 mM HEPES-NaOH, 150 mM NaCl, pH 7.4) was used.
  • Each compound solution was prepared as a dilution series of 3 times the common ratio and 4 concentrations with the concentration shown in Table 13 as the highest concentration using a running buffer as a solvent.
  • a dilution series of a compound solution 100 times the final concentration was prepared using DMSO as a solvent, and then a dilution buffer (1 mM DTT, 10 mM MgCl2, 0.01% Tween20, 10 ⁇ M GDP, 3.03% HBS containing DMSO) was prepared by 100-fold dilution.
  • Biotinylated Avi-tag-fused wild-type KRAS (WT) and mutant KRAS (G12D) were immobilized on the surface of Sensor Chip CAP (Cytiva) coated with Biotin CAPture Reagent in an immobilization amount of about 150-300 RU. was done.
  • the binding evaluation of each compound was performed by the Single Cycle Kinetics method, and a running buffer or compound solution was added to the KRAS non-immobilized surface and the KRAS immobilized surface to obtain the binding response.
  • the flow rate was 100 ⁇ L/min, and 4 different concentrations of compound solutions were intermittently added for 75 seconds from the lowest concentration in the compound addition cycle. The dissociation phase was observed for 3500 seconds.
  • Blank cycles included four intermittent additions of running buffer instead of compound solutions.
  • Biotin CAPture Reagent and KRAS were immobilized for each cycle, and at the end of each cycle, the sensor chip was regenerated with a regeneration solution attached to the Biotin CAPture Kit (Cytiva). Measurements were made at 30°C.
  • the resulting sensorgrams were subjected to Double Reference processing and solvent correction using Biacore Insight Evaluation Software, followed by curve fitting based on a 1:1 binding model.
  • the dissociation constant KD was determined.
  • the table below shows the selectivity for mutant KRAS (G12D) over wild-type KRAS calculated based on the dissociation constant K D for each peptide compound.
  • the present invention provides novel binding molecules with high binding activity and binding selectivity to mutant RAS (G12D).
  • the binding molecules of the present disclosure are useful in fields such as treatment or prevention of diseases associated with expression of mutant RAS (G12D).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2021/017466 2021-05-07 2021-05-07 変異型ｒａｓ（ｇ１２ｄ）に対する選択的結合性を示す結合分子 Ceased WO2022234639A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PCT/JP2021/017466 WO2022234639A1 (ja) 2021-05-07 2021-05-07 変異型ｒａｓ（ｇ１２ｄ）に対する選択的結合性を示す結合分子
CN202280027920.5A CN117177987A (zh) 2021-05-07 2022-05-06 对突变型ras(g12d)显示选择结合性的结合分子
PCT/JP2022/019541 WO2022234851A1 (ja) 2021-05-07 2022-05-06 変異型ｒａｓ（ｇ１２ｄ）に対する選択的結合性を示す結合分子
US18/289,071 US20240239842A1 (en) 2021-05-07 2022-05-06 Binding molecule exhibiting selective binding for ras(g12d) mutant
EP22798955.5A EP4339204A4 (en) 2021-05-07 2022-05-06 BINDING MOLECULE WITH SELECTIVE BINDING PROPERTIES TOWARDS A MUTANT ?????????
JP2023518699A JPWO2022234851A1 (https=) 2021-05-07 2022-05-06

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2021/017466 WO2022234639A1 (ja) 2021-05-07 2021-05-07 変異型ｒａｓ（ｇ１２ｄ）に対する選択的結合性を示す結合分子

Publications (1)

Publication Number Publication Date
WO2022234639A1 true WO2022234639A1 (ja) 2022-11-10

Family

ID=83932681

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2021/017466 Ceased WO2022234639A1 (ja) 2021-05-07 2021-05-07 変異型ｒａｓ（ｇ１２ｄ）に対する選択的結合性を示す結合分子
PCT/JP2022/019541 Ceased WO2022234851A1 (ja) 2021-05-07 2022-05-06 変異型ｒａｓ（ｇ１２ｄ）に対する選択的結合性を示す結合分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/019541 Ceased WO2022234851A1 (ja) 2021-05-07 2022-05-06 変異型ｒａｓ（ｇ１２ｄ）に対する選択的結合性を示す結合分子

Country Status (5)

Country Link
US (1) US20240239842A1 (https=)
EP (1) EP4339204A4 (https=)
JP (1) JPWO2022234851A1 (https=)
CN (1) CN117177987A (https=)
WO (2) WO2022234639A1 (https=)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117603094A (zh) * 2023-11-30 2024-02-27 苏州爱玛特生物科技有限公司 一种氨基保护的2-氨基甲基烯酸衍生物的合成方法
WO2024085235A1 (ja) * 2022-10-20 2024-04-25 中外製薬株式会社 環状ペプチドの結晶の製造方法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080592A1 (en) 2023-10-09 2025-04-17 Incyte Corporation Combination comprising a kras g12d inhibitor and an egfr inhibitor for use in the treatment of cancer
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025080593A1 (en) 2023-10-09 2025-04-17 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI787670B (zh) 2011-12-28 2022-12-21 日商中外製藥股份有限公司 具有環狀部之胜肽化合物及其醫藥組成物
WO2018225851A1 (ja) 2017-06-09 2018-12-13 中外製薬株式会社 Ｎ－置換アミノ酸を含むペプチドの合成方法
PE20221323A1 (es) 2019-11-07 2022-09-09 Chugai Pharmaceutical Co Ltd Compuesto de peptidos ciclicos que tiene accion inhibidora de kras
TW202309065A (zh) 2021-05-07 2023-03-01 日商中外製藥股份有限公司 包含n-取代胺基酸殘基之環狀化合物的製造方法
CA3256645A1 (en) 2022-05-06 2025-04-23 Chugai Seiyaku Kabushiki Kaisha CYCLIC COMPOUND HAVING A SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180319844A1 (en) * 2015-03-11 2018-11-08 California Institute Of Technology Cyclic peptide binder against oncogenic k-ras
US20190119358A1 (en) * 2016-04-15 2019-04-25 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
WO2020230780A1 (ja) * 2019-05-14 2020-11-19 一丸ファルコス株式会社 Ｒａｓ阻害ペプチド
US20210032293A1 (en) * 2019-07-19 2021-02-04 Institute For Systems Biology KRAS-Specific Capture Agents, Compositions, and Methods of Making and Using
JP6880352B1 (ja) * 2019-11-07 2021-06-02 中外製薬株式会社 Ｋｒａｓ阻害作用を有する環状ペプチド化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI787670B (zh) 2011-12-28 2022-12-21 日商中外製藥股份有限公司 具有環狀部之胜肽化合物及其醫藥組成物
WO2017150732A1 (ja) * 2016-03-03 2017-09-08 中外製薬株式会社 チオール基をアミノ基近傍に有するアミノ酸をｎ末端に持つ非環状ペプチド－核酸複合体、そのライブラリー、およびそれから誘導される環状ペプチド－核酸複合体ライブラリーの製造方法
JP7232758B2 (ja) * 2017-06-09 2023-03-06 中外製薬株式会社 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180319844A1 (en) * 2015-03-11 2018-11-08 California Institute Of Technology Cyclic peptide binder against oncogenic k-ras
US20190119358A1 (en) * 2016-04-15 2019-04-25 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
WO2020230780A1 (ja) * 2019-05-14 2020-11-19 一丸ファルコス株式会社 Ｒａｓ阻害ペプチド
US20210032293A1 (en) * 2019-07-19 2021-02-04 Institute For Systems Biology KRAS-Specific Capture Agents, Compositions, and Methods of Making and Using
JP6880352B1 (ja) * 2019-11-07 2021-06-02 中外製薬株式会社 Ｋｒａｓ阻害作用を有する環状ペプチド化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SOGABE, S. ET AL.: "Crystal Structure of a Human K- Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d", ACS MEDICINAL CHEMISTRY LETTERS, vol. 8, 2017, pages 732 - 736, XP055868451, DOI: 10.1021/acsmedchemlett.7b00128 *
ZHANG, Z. ET AL.: "GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf", ACS CENTRAL SCIENCE, vol. 6, 2020, pages 1753 - 1761, XP055935151, DOI: 10.1021/acscentsci.0c00514 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024085235A1 (ja) * 2022-10-20 2024-04-25 中外製薬株式会社 環状ペプチドの結晶の製造方法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080592A1 (en) 2023-10-09 2025-04-17 Incyte Corporation Combination comprising a kras g12d inhibitor and an egfr inhibitor for use in the treatment of cancer
WO2025080593A1 (en) 2023-10-09 2025-04-17 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
CN117603094A (zh) * 2023-11-30 2024-02-27 苏州爱玛特生物科技有限公司 一种氨基保护的2-氨基甲基烯酸衍生物的合成方法
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Also Published As

Publication number Publication date
JPWO2022234851A1 (https=) 2022-11-10
CN117177987A (zh) 2023-12-05
EP4339204A4 (en) 2025-07-30
WO2022234851A1 (ja) 2022-11-10
US20240239842A1 (en) 2024-07-18
EP4339204A1 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
WO2022234639A1 (ja) 変異型ｒａｓ（ｇ１２ｄ）に対する選択的結合性を示す結合分子
JP7823181B2 (ja) Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物
JP7179241B1 (ja) 環状ペプチド化合物の医薬用途
WO2022234853A1 (ja) Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物
EP4603105A1 (en) Pharmaceutical composition containing cyclic compound having selective kras inhibitory effect against hras and nras
EP4592308A1 (en) Cyclic compound having selective kras inhibitory effect on hras and nras
AU2014323131B2 (en) Cortistatin analogues for the treatment of inflammatory and/or immune diseases
WO2020111238A1 (ja) ペプチド化合物、またはアミド化合物の脱保護法および固相反応における脱樹脂方法、並びにペプチド化合物の製造方法
JP2010507565A (ja) メタスチン誘導体およびその用途
JPWO2009131191A1 (ja) メタスチン誘導体およびその用途
JP4703181B2 (ja) 新規な多量体分子、その製造方法及び医薬の製造のためのその使用
HK40095655A (zh) 对突变型ras(g12d)显示选择结合性的结合分子
KR20240082196A (ko) Hras 및 nras에 대해서 선택적인 kras 저해 작용을 갖는 환상 화합물을 포함하는 의약 조성물
WO2024043250A1 (ja) 環状ペプチドまたはその塩、およびｍｄｍｘ阻害剤
HK40096352A (zh) 环状肽化合物的药物用途
HK40052155B (zh) 二聚的肽-磷脂缀合物的优化方法
WO2000004042A1 (fr) Composes peptidiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21939832

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21939832

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP